Methods for depletion and enrichment

Particles with capture sites are used to isolate biomarkers and remove interfering substances, enhancing diagnostic test accuracy by up to 99% and ensuring reliable results.

JP2024160337AInactive Publication Date: 2024-11-13VERAVAS INC
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2024134560
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-07-27
Filing Date
2024-08-09
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current diagnostic tests are susceptible to interference from substances like biotin, leading to inaccurate results, especially in immunoassays, which can cause false negatives or positives, impacting patient treatment and workflow efficiency.

Method used

The use of particles with capture sites to isolate biomarkers and remove interfering substances from biological samples, such as biotin, by forming particle complexes, followed by separation methods like magnetic or chemical separation, to enhance test accuracy.

Benefits of technology

This method effectively reduces interfering substances by up to 99% and improves diagnostic test accuracy, ensuring reliable and precise results without disrupting laboratory workflow.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160337000001_ABST
    Figure 2024160337000001_ABST
Patent Text Reader

Abstract

To provide simple, inexpensive, automatable and effective solutions to eliminate or minimize sample-interfering substances and enrich the biomarker concentration prior to diagnostic testing without impacting the laboratory workflow or turnaround time.SOLUTION: A method for isolating a biomarker from a biological sample comprises: a) combining the sample with a particle comprising a capture moiety to provide a mixture; and b) mixing the mixture to provide particle complexes with the biomarker; thereby isolating the biomarker from the biological sample.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Patent Application No. 62 / 711,391, filed July 27, 2018. The entire contents of the aforementioned application are incorporated herein by reference.

[0002] (Technical field) The present invention relates to methods of using particles (e.g., microparticles, nanoparticles; magnetic, non-magnetic) that include a surface with capture moieties as described herein to isolate biomarkers for subsequent removal or enrichment applications prior to diagnostic testing. [Background technology]

[0003] Clinical testing plays an important role in health assessment, health care, and ultimately public health, affecting people at all stages of life. Most people will undergo one or more clinical tests during their lifetime. In the United States alone, an estimated 7-10 billion clinical tests are performed each year, and clinical test results influence approximately 70% of medical decisions.

[0004] Additionally, since the Centers for Medicare & Medicaid Services (CMS) implemented the new Clinical Laboratory Fee Schedule (CLFS) required by the Protecting Access to Medicare Act (PAMA) in January 2018, PAMA has reduced reimbursement for clinical testing. It is even more important that laboratory results are accurate the first time, and troubleshooting efforts are reduced or time-saving and do not impact laboratory workflow.

[0005] Interfering substances are substances present in a patient sample that can change the correct value of a diagnostic test result, for example by interfering with antibody binding, or can increase or decrease the assay signal by mechanisms of cross-linking, steric hindrance, or autoantibodies. While it is known that immunoassays are susceptible to interferences, clinical laboratories may still report erroneous results if the erroneous results are not recognized by the instrument (analyzer) or laboratory, there is no warning signal, or the physician does not inform the laboratory that the patient's results do not match the clinical picture. Without practical means to identify such samples that may cause problems in advance, unexpected inaccurate results may occur with any sample. Such interferences may result in erroneous results resulting in false negative and false positive test results, which may affect the patient's treatment, leading to unnecessary invasive, diagnostic, or therapeutic measures, or failure to treat the patient.

[0006] Despite the problems arising from interference, screening and diagnostic testing of biomarkers can be difficult, for example due to their low abundance or abundance in biological samples.

[0007] Thus, while biomarkers in the body can be used to detect, predict, and manage disease, many are present in abundance too low to be detected using currently commercially available tests. There is an unmet clinical need for new diagnostic technologies to improve the accuracy of tests, measure hard-to-find biomarkers, reduce the cost, and prepare clinical samples to ultimately save lives.

[0008] Biotin, also known as vitamin B7, is a water-soluble B vitamin commonly found in multivitamins, as well as over-the-counter health and beauty supplements. In vitro clinical diagnostic tests using the streptavidin-biotin binding mechanism can be affected by high blood biotin concentrations. Biotin can be covalently bound to a variety of targets - from large antibodies to steroid hormones - with minimal impact on specific non-covalent binding with avidin, streptavidin, or neutravidin proteins. Therefore, biotin is frequently used in various forms of immunoassay detection systems.

[0009] Immunoassays are generally classified as either sandwich immunoassays (non-competitive) or competitive inhibition immunoassays. Generally, streptavidin-biotin binding is used to streptavidin-coat a surface during assay incubation to couple biotinylated antibodies in sandwich immunoassays or biotin antigens in competitive immunoassays. If the biological sample contains an excess of biotin, it will compete with the biotinylated antibodies or antigens for binding to the streptavidin-coated surface, resulting in reduced capture of the biotinylated antibodies or antigens. In sandwich immunoassays, excess biotin will give falsely low results because the assay signal is directly proportional to the concentration of the sample. In competitive immunoassays, excess biotin will give falsely high results because the assay signal is inversely proportional to the concentration of the sample.

[0010] Normal blood biotin concentrations due to diet and normal metabolism are too low (<1 ng / mL) to interfere with biotinylated immunoassays. However, taking high doses of biotin supplements (e.g., 5 mg or more) can significantly increase blood concentrations that may interfere with commonly used biotinylated immunoassays. In some disease states, extremely high biotin doses (e.g., 100 mg or more) can result in serum or plasma concentrations of over 1000 ng / mL.

[0011] In biotin-based immunoassays, biotin in blood or other samples collected from patients who have ingested high concentrations of biotin can lead to falsely high or falsely low results, depending on the design of the assay. Inaccurate test results can lead to misdiagnosis as well as inappropriate patient management.

[0012] Biotin interferent thresholds vary widely between assays, even on a single platform. Tests with a biotin interferent threshold below 51 ng / mL are considered high-risk tests or weak immunoassays and competitive methods.

[0013] Thus, there is a clinical need for a simple, inexpensive, automatable and effective solution to remove or minimize sample interferents and enrich biomarker concentrations prior to diagnostic testing without impacting laboratory workflow and turnaround time. Summary of the Invention [Means for solving the problem]

[0014] Described herein is a method for simple, effective, and cost-effective conditioning of biological samples to control and reduce a number of known sample-specific interfering substances that may result in erroneous test results and may pose increased risks to patient safety, such as heterophilic antibodies in patients undergoing treatment with mouse monoclonal antibodies or patients who have received mouse monoclonal antibodies for diagnostic purposes. The methods described herein can also control and reduce sample-specific interferences arising from biotin, which may be derived from over-the-counter (OTC) supplements, multivitamins, and botanical herbal medicines taken by consumers for health, beauty, weight loss, or treatment, such as the treatment of multiple sclerosis.

[0015] Also described herein are methods for enriching or increasing the concentration of a biomarker in a biological sample.

[0016] In one aspect, provided herein is a method of isolating a biomarker from a biological sample, comprising: a) combining the sample with particles comprising capture sites to provide a mixture; and b) mixing the mixture to provide a particle complex with the biomarker, thereby isolating the biomarker from the biological sample.

[0017] In one aspect, provided herein is a method of removing interferents from a biological sample, comprising: a) combining the sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide particle complexes with the interferents; and c) removing or completely removing the particle complexes to provide a depleted solution, thereby reducing or decreasing the amount (e.g., mass, molar, concentration) of the interferents. [Brief description of the drawings]

[0018] [Figure 1] FIG. 1 shows a scheme of a confirmation and disqualification assay based on the removal (or depletion) of interfering substances from a biological sample by the particles described herein. [Diagram 2] FIG. 2 shows a scheme of a depletion assay based on the removal (or depletion) of interfering substances from a biological sample by the lyophilized particles described herein. [Diagram 3] FIG. 3 shows a scheme of the depletion assay based on the removal (or depletion) of interferents from a biological sample by magnetized pipette tips as described herein. [Figure 4] FIG. 4 is a graph showing biotin concentration over time after biotin ingestion. [Diagram 5] FIG. 5 is a graph showing biotin depletion. [Figure 6] FIG. 6 is a graph showing biotin depletion. [Figure 7] FIG. 7 is a graph showing biotin concentration over time after biotin ingestion. [Figure 8]FIG. 8 is a graph showing biotin concentrations after taking different doses of biotin. [Figure 9] FIG. 9 is a graph showing biotin depletion. [Figure 10] FIG. 10 is a graph showing PTH concentrations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Described herein are methods for depleting or concentrating a biological sample, comprising combining a particle as described herein with a biological sample as described herein.

[0020] In one aspect, described herein is a method of isolating a biomarker from a biological sample, comprising: a) combining the sample with particles comprising capture sites to provide a mixture; and b) mixing the mixture to provide a particle complex with the biomarker, thereby isolating the biomarker from the biological sample.

[0021] In some embodiments, the method further comprises subjecting the particle complex to a diagnostic test.

[0022] In one aspect, provided herein is a method of removing interferences from a biological sample, comprising: a) combining the sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide particle complexes with interferents; and c) removing or completely removing the particle complexes to provide a depleted solution, thereby reducing or decreasing the amount (e.g., mass, molar, concentration) of interferents.

[0023] In some embodiments, the method further comprises subjecting the depleted solution to characterization (eg, a diagnostic test).

[0024] In some embodiments, the particles are provided as a lyophilizate (eg, LyoSphere™ (BIOLYOPH LLC)).

[0025] In one aspect, provided herein is a method for improving the accuracy of a diagnostic test, comprising: a) combining a biological sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide particle complexes with interfering substances; c) removing, or completely removing, the particle complexes to provide a depleted solution; and d) subjecting the depleted solution to a diagnostic test, thereby improving the accuracy of the diagnostic test.

[0026] In some embodiments, at least 1%, 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99% of the interferents are removed compared to a biological sample not subjected to the method. In some embodiments, a sufficient amount of the interferents are removed to provide less than 100 ppm of interferents in the biological sample. In some embodiments, a sufficient amount of the interferents are removed to provide less than detectable amounts of interferents in a diagnostic test.

[0027] In some embodiments, the capture moiety is a human anti-animal antibody (e.g., mouse IgG, sheep IgG, goat IgG, rabbit IgG, bovine IgG, porcine IgG, horse IgG). In some embodiments, the capture moiety is a heterophile antibody (e.g., FR (Fc specific)) Fab, F(ab)'2, polymerized IgG (type 1, 2a, 2b IgG and IgG fragments, serum components). In some embodiments, the capture moiety is an assay-specific binding agent (e.g., biotin, fluorescein, anti-fluorescein poly / Mab, anti-biotin poly / Mab, streptavidin, neutravidin). In some embodiments, the capture moiety is an assay-specific signal molecule (e.g., HRP, ALP, acridinium ester, isoluminol / luminol, ruthenium, N-(4-aminobutyl)-N-ethylisoluminol (ABEI) / cyclic ABEI). In some embodiments, the capture moiety is an assay-specific blocking agent (e.g., BSA, fish skin gelatin, casein, ovalbumin, PVP, PVA). In some embodiments, the capture moiety is an assay-specific binding linker (e.g., LC, LC-LC, PEO4, PEO16). In some embodiments, the capture moiety is an antigen autoantibody (e.g., free T3, free T4). In some embodiments, the capture moiety is a protein autoantibody (e.g., MTSH, TnI, TnT, non-cardiac TnT (skeletal muscle disease)). In some embodiments, the capture moiety is a chemiluminescent substrate (e.g., luminol, isoluminol, isoluminol derivatives, ABEI, ABEI derivatives, ruthenium, acridinium esters), or a fluorescent label (fluorescein or other fluorophores, and stains). In some embodiments, the capture moiety is streptavidin, neutravidin, avidin, polyA, polyDT, an aptamer, an antibody, Fab, F(ab)'2, an antibody fragment, a recombinant protein, an enzyme, a protein, a biomolecule, or a polymer. In some embodiments, the capture moiety is biotin, fluorescein, polyDT, polyA, an antigen, or the like.

[0028] In some embodiments, the removal, or complete removal, is a separation. In some embodiments, the separation includes physical separation. In some embodiments, the separation includes magnetic separation. In some embodiments, the magnet for magnetic separation is a multi-magnet device with 2-12 magnets in a rack designed to hold 1-12 sample preparation tubes on a large pipetting device. Examples of such pipetting devices include, but are not limited to, those manufactured by Hamilton or Tecan. In some embodiments, the magnet for magnetic separation is a multi-magnet device with 96 or 384 magnets designed to magnetize 96-well or 384-well microtiter plates. In some embodiments, the separation includes chemical separation. In some embodiments, the removal, or complete removal, includes centrifugation at 1000×g or greater for at least 1 minute, 2 minutes, 3 minutes, 4 minutes, or 5 minutes to provide a pellet and supernatant, and removing the supernatant. In some embodiments, the removal, or complete removal, includes filtration (e.g., through a filter). In some embodiments, the filter is porous or has a molecular weight cut-off (MWCO) sufficiently smaller than the diameter of the particles (e.g., nanoparticles, microparticles). In some embodiments, the filtration is by gravity, vacuum, or centrifugation. In some embodiments, the removal, or complete removal, includes magnetization. In some embodiments, the magnetization occurs using a strong magnet (e.g., a neodymium magnet) to provide a pellet and supernatant. In some embodiments, the magnet is in the centrifuge rotor. In some embodiments, the magnet is a magnet in a disposable pipette tip, cover, or sheath.

[0029] In one aspect, provided herein is a method for isolating a biomarker from a biological sample, comprising: a) combining the sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide a particle complex comprising the biomarker; c) removing the particle complex from the mixture; and d) adding a cleavage or release agent to the mixture to provide an isolate comprising the biomarker, thereby isolating the biomarker from the biological sample. In some embodiments, the method for isolating the biomarker from the biological sample is performed prior to performing a diagnostic test on the biological sample.

[0030] In one aspect, provided herein is a method for determining whether a biomarker is present in a biological sample comprising: a) combining the sample with capture sites to provide a mixture; b) combining the mixture with particles comprising capture sites to provide a tertiary complex; c) removing the tertiary complex from the mixture to provide an isolate; and d) determining whether an indication of the tertiary complex is present in the isolate, thereby determining whether the biomarker is present in the biological sample.

[0031] In one aspect, provided herein is a method for determining whether a biomarker is present in a biological sample comprising: a) combining the sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide particle complexes with interferents; c) removing, or completely removing, the particle complexes to provide a depleted solution; d) combining the depleted solution with second particles comprising a second capture site to provide a second mixture; e) mixing the second mixture to provide a second particle complex comprising the biomarker; f) removing the second particle complex from the second mixture; and g) adding a cleavage or release agent to the second mixture to provide an isolate comprising the biomarker, thereby separating the biomarker from the biological sample.

[0032] In some embodiments, the method further includes washing the particle complexes with a diluent.

[0033] In some embodiments, the cleavage reagent is a disulfide bond reducing agent.

[0034] In some embodiments, the method further includes performing a diagnostic test for the biomarker.

[0035] In one aspect, provided herein is a method for concentrating the amount of biomarker in a sample, comprising: a) adding particles comprising capture sites to the sample to provide a mixture; b) mixing the mixture to provide a particle complex; c) separating the particle complex to provide a pellet and a supernatant; e) removing the supernatant from the pellet; f) washing the pellet with a diluent; and g) eluting the biomarker from the pellet to provide an enriched sample, thereby concentrating the amount of biomarker in the sample. In some embodiments, the method for concentrating biomarker from a biological sample is performed on the biological sample prior to performing a diagnostic test.

[0036] In some embodiments, the biomarker is indicative of traumatic brain injury (TBI). In some embodiments, the biomarker is s-100β, glial fibrillary acidic protein (GFAP), neuronal specific enolase (NSE), neurofilament light chain (NFL), truncated tau protein (C-tau), and ubiquitin C-terminal hydrolase L1 (UCH-L1). In some embodiments, the biomarker is indicative of Alzheimer's disease (AD). In some embodiments, the biomarker is amyloid beta, BACE1, soluble Aβ precursor protein (sAPP). In some embodiments, the biomarker is indicative of a sexually transmitted disease (STD). In some embodiments, the STD is chlamydia, gonorrhea, syphilis, trichomonas, HPV, herpes, hepatitis B, hepatitis C, HIV. In some embodiments, the biomarker is indicative of a bacterial infection. In some embodiments, the biomarker is a bacterial capture site. In some embodiments, the biomarker is cleaved from the complex by a cleavage reagent. In some embodiments, the presence of the biomarker is determined by MALDI-MS. In some embodiments, the presence of the biomarker is determined by molecular diagnostics. In some embodiments, the presence of the biomarker is determined by immunoassay.

[0037] In some embodiments, the interfering substance is fibrinogen, and the removal or complete removal is a separation, such as a physical separation by centrifugation, and the particle complex is trapped in the thrombus.

[0038] According to Figure 1, the scheme shows a confirmatory or disqualifying assay based on the removal (or depletion) of interfering substances from a biological sample by particles as described herein. A biological sample is aspirated from a primary blood collection tube (PBCT) and dispensed into a secondary transfer tube (STT). Particles as described herein, for example particles containing a surface with capture sites for free biotin and / or heterophilic antibodies, are added to the STT to bind and deplete interfering substances from the sample.

[0039] In Figure 2, a scheme illustrates a depletion assay based on the removal (or depletion) of interferents from a biological sample by lyophilized particles described herein: Lyophilized particles (e.g., as described herein) receive a biological sample, resulting in resuspension and dispersion of the particles and the biological sample.

[0040] In Figure 3, a scheme shows a depletion assay based on the removal (or depletion) of interferents from a biological sample by a magnetized pipette tip as described herein. A micropipette tip equipped with a magnet is added to the biological sample to remove interferents as described herein or biomarkers as described herein from the biological sample.

[0041] (Method of separation) The particles described herein can be added to a collection device, such as a primary blood collection tube, a 24-hour urine collector, a urine collector, a saliva collection tube, a urinary collection tube, a semen collector, a blood collection bag, or any sample collection tube or device, prior to adding a biological sample.

[0042] The particles described herein can also be added to a sample after collection into a collection device or after transfer of the sample from a first collection device to a storage or transfer device, such as a plastic or glass tube, vial, bottle, beaker, flask, bag, can, microtiter plate, ELISA plate, 96-well plate, 384-well plate, 1536-well plate, cuvette, reaction module, reservoir, or any container suitable for holding, storing, or processing a liquid sample.

[0043] In some embodiments, the particles described herein are added to a collection device that contains a biological sample, hi some embodiments, the particles described herein are added to the collection device prior to adding the biological sample.

[0044] In one aspect, described herein is a device for releasing particles (i.e., a screw cap that triggers a release mechanism) that includes a collection device described herein that contains a biological sample, such as a urine collector. For example, the device is a tube with a screw cap that releases particles described herein upon closing of the screw cap.

[0045] In one aspect, described herein are devices that include chemicals that release particles into a vessel containing a biological sample (i.e., an encapsulated composition or a composition that dissolves into solution at a defined rate or time point). In some embodiments, the devices described herein are configured to delay the addition of the particles described herein, for example, to provide pre-treatment of the sample prior to a diagnostic test.

[0046] In some embodiments, the samples described herein can be pretreated with chemicals, proteins, blocking agents, surfactants, or combinations thereof prior to the addition of the particles described herein, for example to adjust the pH, deplete or compete sample-specific interfering substances, and / or address matrix-specific challenges prior to adding, introducing, dispersing, or mixing the nanoparticles with the sample to improve the specificity and binding rate of the nanoparticles to the target biomarker. The delay in adding the nanoparticles to the sample after sample pretreatment can be physically controlled by adding the nanoparticles to the sample after sample pretreatment. The nanoparticles can also be present in the sample during sample pretreatment if they are encapsulated, shielded, or protected by a shell, coating, or polymerization of a chemical, polymer, or sugar such that the chemical, polymer, or sugar must be dissolved before the nanoparticles can be released, added, dispersed, or mixed into the sample. The delayed release of the nanoparticles can use chemicals known to those skilled in the art, such as those used today in delayed drug release technology.

[0047] Methods for magnetic separation of particles

[0048] In one aspect, provided herein are methods of removing interfering substances from a biological sample (e.g., prior to a diagnostic test) or isolating or separating magnetic particles (e.g., in a primary blood collection tube, a custom sample collection device, a secondary transfer tube, or a custom sample device). For example, a magnet-based device will rapidly (less than 2 minutes, preferably less than 30 seconds) separate magnetic nanoparticles to the side and / or bottom to form an essentially particle-free supernatant. The particle-free supernatant can be continuously aspirated without disrupting the particle-containing pellet and dispensed into a separate transfer tube for diagnostic testing. In some embodiments, the pellet is separated or subjected to diagnostic testing.

[0049] Apparatus for magnetic separation of particles

[0050] Provided herein are devices comprising the particles described herein that can be used in the methods described herein, for example, to remove or deplete biomarkers for diagnostic testing. In some embodiments, the devices include a physical mechanism for delaying the combination of the particles described herein with the samples described herein. In some embodiments, the devices described herein include a time release mechanism for delaying the combination of the particles described herein with the samples described herein.

[0051] (Magnetic tube holder) A custom magnetic tube holder that can be inserted into a sample rack or removed from a stand for subsequent diagnostic testing of the particle-free supernatant. The custom magnetic tube holder can be designed to have a physical opening or clear / transparent plastic (where no magnet or magnet array is present) that allows the sample tube barcode to be detected and read by the analyzer and also allows indicator tests such as lipemia, hemolysis, cell debris / thrombus detection, concentration sensing, etc. to be run on the analyzer. The sample tube can be a custom sample tube designed with notches or ridges and grooves that only fit into the custom magnetic tube holder in a specific orientation to allow for the opening (space) of the magnetic tube holder, or the clear / transparent plastic can be custom sample tubes designed to allow the analyst to see and read the barcode and / or run indicator tests such as lipemia, hemolysis, cell debris / thrombus detection, concentration sensing, etc.

[0052] In some embodiments, the magnet can be attached to the sample rack with adhesive, Velcro®, or other methods. Once a sample tube containing magnetic nanoparticles is inserted into the location of the magnet attached to the sample rack, the magnetic nanoparticles instantly segregate to the side and / or bottom of the sample tube, forming an essentially particle-free sample supernatant for diagnostic testing by the sample rack's specific testing platform or analytical device.

[0053] The sample rack itself, as a custom magnetic sample rack, is compatible with a given analytical instrument (e.g., specialized for Abbott ARCHITECT, Siemens ADVIA Centaur XP, Roche cobas e411 / e601 / 602 / e801, Beckman Coulter Access2 / DxI400 / DxI800, DiaSorin LIAISON / LIAISON XL, etc.). For example, every tube position in the rack has an array of magnets designed to instantly separate magnetic nanoparticles to the side and / or bottom of the sample tubes to form an essentially particle-free sample supernatant for diagnostic testing.

[0054] In one aspect, provided herein is an apparatus (eg, a separation apparatus) that includes a holder (eg, a test tube holder) for a rack of test tubes that includes a magnet.

[0055] (Disposable pipette tips) In one aspect, the device is a disposable pipette tip that includes a custom magnet inserted into the disposable tip to rapidly separate magnetic nanoparticles from the essentially particle-free sample supernatant onto the surface of the pipette tip. The disposable pipette tip with the custom magnet can then remove the pellet containing the particles from the sample without disruption. The disposable tip containing the particles can be discarded if the particle capture does not need to be measured or characterized (i.e., depleted of interferents) or may be inserted into a new tube for particle separation and characterization in a subsequent diagnostic test (i.e., enriched). For example, the disposable tip containing the particles can be inserted into a secondary transfer tube containing a buffer. When the magnet is removed from the tip or when the magnet is turned off (e.g., an electromagnet), the particles are released and dispersed into the buffer.

[0056] In one aspect, provided herein is a device that includes a disposable tip that includes a magnet.

[0057] Methods for physical separation of particles

[0058] In one aspect, provided herein is a method for removing particles described herein by physical force (e.g., gravity). In some embodiments, particles described herein are separated, isolated, or removed from a biological sample by physical force (e.g., by centrifugation). In some embodiments, the method is used prior to application of the diagnostic test methods described herein, for example, in a primary blood collection tube, in a custom sample collection tube, in a secondary transfer tube, or in a custom sample device. In some embodiments, the method for removing particles is filtration.

[0059] For example, magnetic nanoparticles specific for fibronectin, and / or other thrombus factors, or for off-off of thrombus components / components, subsequent capture or binding of "thrombus" (in serum), cell debris (i.e., red blood cell membrane specific), and / or magnetic nanoparticles for capture or binding of cell debris (in serum or plasma) can be used to increase centrifugation speed and efficiency (shorter spin times to improve laboratory efficiency, workflow and throughput) through the integration of strong magnets or magnetic technologies in the centrifugation rotor and / or tube holder. The combination of RCF or G of centrifugation and magnetic separation of magnetic nanoparticle complexes (thrombus + magnetic beads, cell debris + magnetic beads) allows for much faster and more efficient separation and formation of a supernatant at the side or bottom of the sample tube, clearing the sample for subsequent analysis. For example, in most laboratories, this centrifugal separation step is 4 minutes or more, and the combination of centrifugation and magnetic isolation / separation of magnetic nanoparticle-thrombus / cell debris complexes can shorten it to 2 minutes or less (preferably 1 minute or less).

[0060] Furthermore, if a nanoparticle or a majority of magnetic nanoparticles are specific for one or more different sample interference mechanisms, such as 1, 5, 10, 20, 30 or more different interference mechanisms, those interferents, if present, will be captured by the nanoparticles and depleted from the sample after physical separation from the centrifugal mass or by a combination of centrifugation and magnetic separation as described above.

[0061] These magnetic nanoparticles also do not require specificity for the thrombus or cell debris to be separated via centrifugation or a combination of centrifugation and magnetic separation in centrifugation, and their surface may be co-coated or immobilized with more than one antigen and / or antibody, where one or more antibodies are specific for the thrombus or cell debris and other antigens and / or antibodies are specific for sample interferents, where the nanoparticles will specifically bind both the sample interferents and the thrombus and / or cell debris for subsequent physical separation or isolation via centrifugation or a combination of centrifugation and magnetic separation.

[0062] The use of nanoparticles specific to the clot and / or cell debris increases the rate of clotting by specifically binding with the magnetic nanoparticles and pulling all to the magnetic body for magnetic separation and isolation. This bead-based pellet formed by the magnetic field and strength also promotes clot formation based on the forced proximity of the clot or clotting factors specifically captured by the nanoparticles and subsequent magnet.

[0063] Methods for chemical separation of particles

[0064] In some embodiments, the particles described herein are separated, isolated, or removed from a biological sample by a chemical separation method, which in some embodiments is used before a diagnostic test method is applied, for example, in a primary blood collection tube, in a custom sample collection device, in a secondary transfer tube, or in a custom sample device.

[0065] In one aspect, provided is a method for chemical separation of particles that includes providing one or more salts, solvents, polymers, or surfactants.

[0066] In some embodiments, chemical separation methods, such as liquid-liquid phase separation, fractionate the particles into phase A and the nanoparticle-free sample into phase B, which is tested. Agents for liquid-liquid phase separation (chemical phase separation) can be salts, soluble polymers, surfactants, etc.

[0067] For example, liquid-liquid phase separation can occur by adding a non-polar solvent such as hexane to a polar aqueous sample, and the particles will partition into the non-polar phase, leaving a nanoparticle-free aqueous phase for testing by diagnostic tests as described herein. In some embodiments, the methods of separation described herein provide nanoparticles in an organic phase. In some embodiments, the methods of separation described herein provide nanoparticles in an aqueous phase.

[0068] A method of isolating particles in a biological sample comprising isolating the particles by providing a non-polar solvent and an aqueous polar solvent to the particles and the biological sample to provide a non-polar solvent layer and a polar solvent layer, removing the non-polar solvent layer containing the non-polar solvent, and isolating the aqueous polar solvent containing the particles.

[0069] Sample recovery can be adjusted or corrected by adding and using an internal standard, such as a deuterated internal standard for LC-MS / MS, before aspirating the non-polar phase to waste.

[0070] In some embodiments, the separation is a physical separation used in combination with magnetic separation. For example, in one aspect, provided is an apparatus (e.g., a magnetized centrifuge, or a centrifuge with a magnet that assists in separation by both gravity and magnetic force of the magnet). In one aspect, provided herein is an apparatus with a magnet and a centrifuge for the separation of particles described herein. In some embodiments, the apparatus significantly reduces the centrifugation time.

[0071] Methods for Removal of Interfering Substances Described herein are methods for removing or minimizing interferents, including depleting (e.g., mitigating, reducing, or controlling) known sources of pre-analytical and analytical testing error (e.g., interference) from hemolysis, lipemia, jaundice, bilirubin, microfibrin clots, cell debris, blood cells, fibrinogen, or other interferents, such as drugs, metabolites, supplements, botanicals, multivitamins, etc. In some embodiments, the methods described herein provide methods for removing interferences due to matrix effects or differences in sample type (e.g., animal species, human species). In some embodiments, the methods described herein provide methods for removing interferents prior to diagnostic testing (e.g., diagnostic testing or biomarker testing in clinical trials). In some embodiments, the methods for removing interferents described herein are used to increase the accuracy and reliability of diagnostic testing of biomarkers described herein in clinical trials. For example, the methods described herein can be used for patient selection or screening, e.g., inclusion or exclusion criteria. In some embodiments, the methods for removal or depletion described herein can be used to identify outliers in clinical data or clinical trial results. For example, outliers in clinical data or clinical trial results include the identification of false positives or false negatives for the biomarkers described herein.

[0072] Depletion is defined as complete if a sufficient amount of the interfering substance or mechanism is captured and / or removed for subsequent quantitative, semi-quantitative, or qualitative analysis with no or reduced interference, partial if a sufficient amount of the interfering substance or mechanism is captured and / or removed for subsequent quantitative, semi-quantitative, or qualitative analysis, and partial if a sufficient amount of the interfering substance or mechanism and internal standard is captured for quantitative, semi-quantitative, or qualitative analysis by measurement methods that can use an internal standard to adjust the recovery of the analyte or biomarker of interest, such as LCMS and LC-MS / MS (i.e., deuterated internal standard) and HPLC (C14 or tritiated internal radioisotope internal standard).

[0073] Depletion does not mean 100% removal of interferences from the sample, but that remaining interferences no longer lead to erroneous results. However, sample pretreatment depletion can remove 100% of interferences if necessary for a specific assay or purpose, such as subsequent elution and analysis by LC-MS / MS, or for sample pretreatment, nucleic acid purification, enrichment for molecular diagnostics, or for enrichment of biomarkers from difficult sample types, such as urine, saliva, stool, etc.

[0074] In some embodiments, the methods described herein are performed for less than 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 24 hours, 20 hours, 16 hours, 12 hours, 8 hours, 4 hours, 2 hours, 1 hour, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or less. In some embodiments, the methods described herein are performed for less than 1 day.

[0075] (Interfering substances) The methods described herein reduce, minimize, or eliminate interfering substances in a biological sample. Interfering substances are substances present in a patient sample that can alter the exact value of a diagnostic test result, for example, by inhibiting antibody binding, or can increase or decrease the assay signal through cross-linking, steric hindrance, or autoantibody mechanisms. As used herein, an "interfering substance" is an endogenous or exogenous substance, or a combination of endogenous and / or exogenous substances, in blood, plasma, serum, CFS, urine, stool, saliva, semen, amniotic fluid, other body fluids or sample matrix, such as immunoglobulins (IgG, IgM, IgA, IgE, IgD), proteins, antigens, lipids, triglycerides, cellular components, contaminants, chemicals, drugs, drug metabolites, supplements, vitamins, botanicals, foreign bodies (viruses, bacteria (gram positive, gram negative), fungi, yeast), and waste products produced by foods or substances in foods that may interfere with the test and cause erroneous test results due to specific or non-specific interactions with the foreign bodies, test materials, formulations, biological and synthetic components, test design, and / or test format.Interfering substances include, but are not limited to, heterophilic or heterophile-like interfering substances such as autoantibodies, rheumatoid factor (RF), human anti-mouse antibodies (HAMA), human anti-animal antibodies (HAAA), such as polyclonal and / or monoclonal antibodies of goat, rabbit, sheep, cow, mouse, horse, pig, and donkey, and chemiluminescent substrates (luminol, isoluminol, isoluminol derivatives, ABEI, ABEI derivatives, ruthenium, acridinium esters), fluorescein or other fluorophores, and Fluorescent labels such as dyes, capture moieties (streptavidin, neutravidin, avidin, captavidin, polyA, polyDT, aptamers, antibodies, Fab, F(ab')2, antibody fragments, recombinant proteins, enzymes, proteins, biomolecules, polymers) and their binding partners (i.e., biotin, fluorescein, polyDT, polyA, antigens, etc.), binding linkers (LC, LC-LC, PEO, PEOn), bovine serum albumin, human serum albumin, ovalbumin, gelatin, mouse, ya The assay specific interferents may be used in the test design or assay formulation, such as purified poly and monoclonal IgG from goat, sheep, and rabbit, etc., polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), triblock copolymers such as Tween-20, Tween-80, TritonX-100, Pluronic® and Tetronic, and commercially available blocking agents, blocking proteins and polymeric blocking reagents from companies such as Surmodics and Scantibodies, that are typically used in the design of sample pretreatment methods and devices for antibody-based diagnostic tests, non-antibody-based diagnostic tests, or subsequent analysis by mass spectrometry (i.e., HPLC, MS, LCMS, LC-MS / MS), radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), molecular diagnostics, lateral flow, point-of-care (PoC), CLIA and CLIA-waived tests and devices.

[0076] In one aspect, provided herein is a method for removing an interferent (e.g., biotin) from a biological sample, comprising providing a particle derivatized with a capture moiety that binds the interferent. In some embodiments, the interferent is biotin.

[0077] In another aspect, samples can be pretreated with particles (e.g., nanoparticles, microparticles) to deplete sex hormone binding globulin (SHBG) or sex steroid binding globulin (SSBG) from serum or plasma such that a SHBG-depleted sample can then be tested to measure free or bioavailable hormones or steroids (i.e., free testosterone). In some embodiments, the interferent is sex hormone binding globulin (SHBG) or sex steroid binding globulin (SSBG).

[0078] In some embodiments, the interfering substance is biotin, HAMA, RF, a heterophile antibody, or an anti-SAv.

[0079] (Methods for Biomarker Removal or Enrichment) Described herein are methods for enriching or increasing the concentration of biomarkers in a biological sample. "Enrichment" is defined as fully or partially capturing particles and binding target analytes or biomarkers to particles from a biological sample (e.g., human or animal serum, plasma, blood, whole blood, processed blood, urine, saliva, stool (liquid and solid), semen or seminal plasma, cells, tissues, biopsies, DNA, RNA, or any liquid or solid). In some embodiments, enrichment includes washing and concentrating the biological sample, for example, by washing and isolating biomarker-specific nanoparticles to remove or minimize interfering substances prior to the biomarker characterization and measurement steps.

[0080] In some embodiments, the methods described herein are used to separate and purify specific targets (e.g., biomarkers) in a biological sample for subsequent elution and testing, or to enrich or increase the concentration of the biomarker prior to a diagnostic test.

[0081] After washing or isolation of the biomarker-specific particles, prior to the characterization or measurement step, the particles can be dispersed, reconstituted, or resuspended in a buffer, such as phosphate buffered saline (i.e., PBS pH 7.2), or an LC-MS / MS compatible buffer. This means that the critical characterization or measurement step of the biomarkers captured and concentrated by the particles was performed in a buffer system and not in an animal or human matrix that would introduce or cause matrix effects or bias between biomarkers measured in animal blood, plasma, serum, or urine compared to the same biomarkers measured in blood, plasma, serum, or urine using the same characterization, measurement, or testing method or system. Washing allows for the washing away of sample matrices, components, proteins, cellular components, and associated interferences or matrix effects.

[0082] Enrichment is defined as complete when a sufficient amount of analyte is captured for subsequent diagnostic testing, e.g., quantitative, semi-quantitative, or qualitative analysis, partial when a sufficient amount of analyte or biomarker is captured for subsequent semi-quantitative or qualitative analysis, and also when a sufficient amount of the target analyte or biomarker and internal standard are captured for quantitative, semi-quantitative, or qualitative analysis by measurement methods that can use an internal standard to adjust the recovery of the analyte or biomarker of interest, such as LCMS and LC-MS / MS (i.e., deuterated internal standard) and HPLC (C14 or tritium internal radioisotope internal standard).

[0083] Provided herein are methods for concentrating biomarkers in a sample prior to diagnostic testing, comprising: a) adding particles (e.g., nanoparticles, microparticles) to a sample, b) mixing the particles (e.g., nanoparticles, microparticles) with the sample, c) incubating the particles (e.g., nanoparticles, microparticles) with the sample to allow the biomarkers to bind and capture on the particles (e.g., nanoparticles, microparticles), d) isolating or removing the particles (e.g., nanoparticles, microparticles) from the sample, e) storing the particles (e.g., nanoparticles, microparticles), f) washing the particles (e.g., nanoparticles, microparticles) with a suitable diluent to remove non-specific material, g) measuring the amount, mass, molar concentration, concentration, or yield of biomarker captured on the particles (e.g., nanoparticles, microparticles) using a biomarker-specific quantitative, semi-quantitative, or qualitative diagnostic test. In some embodiments, the diluent comprises water (e.g., deionized water, water for injection, saline, aqueous buffer solution).

[0084] In some embodiments, the enrichment methods described herein include a washing step, which removes interfering substances as described herein and / or provides a washed, purified, or isolated biomarker of interest (e.g., a biomarker as described herein). In some embodiments, the enrichment methods described herein reduce matrix effects or species effects. In some embodiments, the enrichment methods described herein are used prior to a diagnostic test that compares two biological samples of different origins. In some embodiments, the enrichment methods described herein are used prior to a diagnostic test that compares an animal sample to a human sample. In some embodiments, the enrichment methods described herein are used prior to a diagnostic test that compares a serum sample to a plasma sample. In some embodiments, the enrichment methods described herein are used for samples with high viscosity.

[0085] In some embodiments, the enrichment method includes combining a first biological sample enriched in biomarkers with a second biological sample enriched in biomarkers.

[0086] Provided herein are methods for cleaving cleavage ... Displacers or displacing agents, competitive elution (e.g., counter-ligands or analogs at >0.1 M), ionic strength and / or chaotropic effects (e.g., NaCl, KCl, 3.5-4.0 M magnesium chloride in 10 mM Tris at pH 7.0, 5 M lithium chloride in 10 mL of phosphate buffer at pH 7.2, 2.5 M sodium iodide at pH 7.5, 0.2-3.0 M sodium thiocyanate), surfactants, detergents, concentrated inorganic salts, denaturing (e.g., 2-6 M guanidine HCl, A method for measuring the amount, mass, molar concentration, or yield of a target biomarker captured and enriched by a particle (e.g., nanoparticle, microparticle) by being eluted, dissociated, or released from the particle (e.g., nanoparticle, microparticle) by disruption of binding interactions using elution strategies such as elution of eluates, disulfide bond reducing agents (e.g., 2-8 M urea, 1% deoxycholate, 1% SDS), organic solvents (e.g., alcohol, chloroform, ethanol, methanol, acetonitrile, hexane, DMSO, 10% dioxane, 50% ethylene glycol at pH 8-11.5 (also chaotropic), radiation or heat (high temperature), conformational changes, disulfide bond reducing agents (2-mercaptoethanol, dithiothreitol, tris(2-carboxyethyl)phosphine), enzyme inactivation, chaotropic agents (urea, guanidine chloride, lithium perchlorate), mechanical agitation, sonication, and protein digesting enzymes (pepsin, trypsin), and combinations thereof.

[0087] Unless otherwise stated or implied from this disclosure, any of the embodiments described in connection with a particular method or composition described herein can be used in combination with any of the other embodiments described herein.

[0088] The methods and compositions of the present invention can be used in combination with any suitable assay known in the art, for example, any suitable affinity assay or immunoassay known in the art, including, but not limited to, protein-protein affinity assays, protein-ligand affinity assays, nucleic acid affinity assays, indirect fluorescent antibody assays (IFAS), enzyme-linked immunosorbent assays (ELISA), radioimmunoassays (RIA), and enzyme immunoassays (EIA), direct or indirect assays, competitive assays, sandwich assays, CLIA or CLIA-waived tests, LC-MS / MS, analytical assays, and the like.

[0089] Both methods of depleting sample interferents and enriching biomarkers from the same sample prior to a diagnostic test consist of a) adding chemical and / or biological reagents, additives or compositions to the sample to block or deplete sample-specific interferences prior to adding biomarker-specific particles (e.g., nanoparticles, microparticles) to the sample, b) pretreating or incubating the sample with chemical and / or biological reagents, additives or compositions before adding biomarker-specific particles (e.g., nanoparticles, microparticles) to the sample, c) incubating the biomarker-specific particles (e.g., nanoparticles, microparticles) with the sample to allow the target biomarkers to bind and be captured by the particles (e.g., nanoparticles, microparticles), d) washing or isolating the particles (e.g., nanoparticles, microparticles) from the sample and the chemical and / or biological reagents, additives or compositions, and e) characterizing the biomarkers captured and enriched on the particles (e.g., nanoparticles, microparticles) using a diagnostic test.

[0090] For example, in one embodiment, a particle bound to captavidin will bind to biotin in a sample at neutral pH. Biotin bound to captavidin will release the biotin when the pH is raised to 10.

[0091] (Biomarkers) Described herein are methods for isolating or concentrating biomarkers present in a biological sample. As used herein, a "biomarker" is defined as a characteristic biological indicator or biologically derived indicator (e.g., a metabolite) of a progression, event, or condition, such as aging or disease. Biomarkers may be endogenous and / or exogenous analytes, antigens, small molecules, large molecules, drugs, therapeutic agents, metabolites, xenobiotics, chemicals, peptides, proteins, protein digests, viral antigens, bacteria, cells, cell lysates, cell surface markers, antigenic determinants, antibodies, antibody fragments, IgG, IgM, IgA, IgE, IgD receptors, receptor ligands, hormones, hormone receptors, enzymes, enzyme substrates, single-stranded oligonucleotides, single-stranded polynucleotides, double-stranded oligonucleotides, double-stranded polynucleotides, polymers, and aptamers. In some embodiments, the biomarker is an interfering substance as described herein (e.g., a substance present in a patient sample that can alter the true value of a diagnostic test result by inhibiting antibody binding, or that can increase or decrease the assay signal by mechanisms of cross-linking, steric hindrance, or autoantibodies).As used herein, "interfering substances" refers to heterophilic or heterophile-like interfering substances, such as, but not limited to, autoantibodies, rheumatoid factors (RF), human anti-mouse antibodies (HAMA), human anti-animal antibodies (HAAA), such as polyclonal and / or monoclonal antibodies of goat, rabbit, sheep, cow, mouse, horse, pig, and donkey, and chemiluminescent substrates (luminol, isoluminol, isoluminol derivatives, ABEI, ABEI derivatives, ruthenium, acridinium esters), fluorescein, or other interfering substances. Fluorescent labels such as fluorophores and dyes, capture moieties (streptavidin, neutravidin, avidin, polyA, polyDT, aptamers, antibodies, Fab, F(ab')2, antibody fragments, recombinant proteins, enzymes, proteins, biomolecules, polymers) and their binding partners (i.e., biotin, fluorescein, polyDT, polyA, antigens, etc.), binding linkers (LC, LC-LC, PEO, PEOn), bovine serum albumin, human serum albumin, ovalbumin, gelatin, mouse, Assay specific interferents used in test design or assay formulation may be purified poly and monoclonal IgG such as goat, sheep, and rabbit, polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), triblock copolymers such as Tween-20, Tween-80, TritonX-100, Pluronic® and Tetronic, and commercially available blocking agents, blocking proteins and polymeric blocking reagents from companies such as Surmodics and Scantibodies, typically used in the design of sample pretreatment methods and devices for antibody-based diagnostic tests, non-antibody-based diagnostic tests, or subsequent analysis by mass spectrometry (i.e., HPLC, MS, LCMS, LC-MS / MS), radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), molecular diagnostics, lateral flow, point of care (PoC), CLIA and CLIA-waived tests and devices. In some embodiments, the biomarkers are identified in biological samples as described herein.

[0092] (Fibrinogen) Fibrinogen is converted to fibrin by thrombin upon tissue or vascular injury, resulting in the formation of a fibrin-based clot. In some embodiments, the particles described herein (e.g., particles derivatized with antifibrinogen (e.g., mouse antifibrinogen)) used in the methods described herein bind fibrinogen in whole blood, allowing for separation (e.g., chemical separation). Particles bound to the clot via fibrin can be isolated and removed from the serum after centrifugation for particle-free serum testing. In some embodiments, the biomarker is fibrinogen. In some embodiments, the methods described herein use antifibrinogen-derivatized particles to eliminate the need for centrifugation of the sample (e.g., blood sample).

[0093] (Traumatic Brain Injury) In some embodiments, the biomarker is for traumatic brain injury. There are nine (9) biomarkers associated with the severity and magnitude of acute brain injury and blood-brain barrier (BBB) ​​integrity, but they are present at extremely low circulating concentrations and are very difficult to detect and quantitate using existing immunoassay techniques and testing platforms. The Banyan BTI test (FDA approved on February 14, 2018) measures only two of those biomarkers, but the methods and devices (e.g., enrichment methods, devices for enrichment) described herein can simultaneously measure all nine biomarkers in a patient and aid in the diagnosis and prognosis of the patient. Particles derivatized with capture sites for each of the nine biomarkers may be added to a biological sample from a patient suspected of TBI. In some embodiments, the biomarker for traumatic brain injury is selected from the group consisting of S100B, GFAP, NLF, NFH, gamma-enolase (NSE), alpha-II spectrin, UCH-L1, total tau, and phosphorylated tau. In some embodiments, the biomarkers for traumatic brain injury are selected from GFAP and UCH-L1.

[0094] In some embodiments, the methods (e.g., enrichment methods) described herein are used to isolate or enrich for 1, 2, 3, 4, 5, 6, 7, 8, or 9 traumatic brain injury biomarkers selected from the group consisting of S100B, GFAP, NLF, NFH, gamma-enolase (NSE), alpha-II spectrin, UCH-L1, total tau, and phosphorylated tau.

[0095] (Alzheimer's Disease) In some embodiments, the biomarker is for Alzheimer's disease. There are two (2) types of biomarkers associated with the severity and magnitude of Alzheimer's disease. In some embodiments, the biomarker for Alzheimer's disease is selected from the group consisting of amyloid beta, BACE1, and soluble Aβ precursor protein (sAPP). In some embodiments, the biomarker for Alzheimer's disease is selected from the group consisting of beta amyloid (1-42), phospho-tau (181p), and total tau. In some embodiments, the methods (e.g., enrichment methods) described herein are used to isolate or enrich one, two, or three biomarkers for Alzheimer's disease selected from the group consisting of amyloid beta, BACE1, and soluble Aβ precursor protein (sAPP). In some embodiments, the biomarker is amyloid beta, BACE1, or soluble Aβ precursor protein (sAPP). In some embodiments, the biomarker for Alzheimer's disease is identified in a biological sample (e.g., CSF).

[0096] (sexually transmitted diseases) In some embodiments, the biomarkers are for sexually transmitted diseases (STDs). There are at least ten (10) biomarkers characteristic of STD infection. In some embodiments, the STD biomarkers are biomarkers for chlamydia, gonorrhea, syphilis, trichomonas, HPV, herpes 1 and 2, HSV, hepatitis A, hepatitis B, hepatitis C, HIV 1 and 2. In some embodiments, the methods (e.g., enrichment methods) described herein are used to isolate or enrich for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 STD biomarkers: chlamydia, gonorrhea, syphilis, trichomonas, HPV, herpes 1 and 2, HSV, hepatitis A, hepatitis B, hepatitis C, HIV 1 and 2, and HIV antibodies. In some embodiments, the biomarkers are present in urine (e.g., chlamydia, gonorrhea, trichomonas). In some embodiments, the biomarkers are present in blood, serum, or plasma (e.g., syphilis, HPV, herpes 1 and 2, HSV, Hepatitis A, Hepatitis B, Hepatitis C, HIV 1 and 2, HIV antibodies).

[0097] (Bacterial infection) In some embodiments, the biomarker is for bacterial infection. The current gold standard test for bacterial infection is blood culture, which can take 24-48 hours before a positive result is reflected in a confirmatory test, such as a molecular diagnostic. Described herein are methods for ruling out / ruling out bacterial infection in a reduced time frame, e.g., 60 minutes or less (e.g., 50 minutes, 40 minutes, 30 minutes, 20 minutes or less), as short as 30 minutes or less, which is critical to successfully treat a patient to prevent or manage sepsis. There are at least 30 (30) biomarkers characteristic of bacterial infection. In some embodiments, the bacterial biomarker is selected from the group consisting of biomarkers for bacterial species that cause sepsis (e.g., Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus). In some embodiments, the biomarker is a biomarker for Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus. In some embodiments, the biomarker is a biomarker for Gram-positive or Gram-negative bacteria. In some embodiments, the biomarker is a biomarker for a yeast pathogen (e.g., a yeast pathogen associated with a bloodstream pathogen).

[0098] In some embodiments, the Gram-positive bacteria is Enterococcus, Listeria monocytogenes, Staphylococcus, Staphylococcus aureus, Streptococcus, Streptococcus agalactiae, Streptococcus pneumoniae, or Streptococcus pyogenes.

[0099] In some embodiments, the gram-negative bacterium is Acinetobacter baumannii, Haemophilus influenzae, Neisseria meningitides, Pseudomonas aeruginosa, Enterobacteriaceae, Enterobacter cloacae complex, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus, or Serratia marcescens.

[0100] In some embodiments, the yeast pathogen is Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, or Candida tropicalis.

[0101] In some embodiments, mass spectrometry is followed. A method is envisaged in which a cleavage agent (e.g., a reducing agent (e.g., DTT or TCEP)) is added to the bacteria-particle binding complex to cleave the linker (i.e., the linker that connects the particle to the surface capture moiety). The resulting bacteria are cultured or analyzed by MALDI-TOF mass spectrometry.

[0102] A method is envisioned in which a cleaving agent (e.g., a reducing agent (e.g., DTT or TCEP)) is added to the bacteria-particle bound complex to cleave the linker (i.e., the linker that attaches the particle to the surface capture moiety). The resulting bacteria are cultured or analyzed by MALDI-TOF mass spectrometry or by molecular diagnostics such as BioFire Diagnostics' FilmArray® Blood Culture Identification (BCID) Panel.

[0103] (thyroid function) TSH concentrations are measured as part of thyroid function testing in patients suspected of having thyroid hormone excess (hyperthyroidism) or deficiency (hypothyroidism). The methods described in some embodiments herein are used to assess thyroid function. In some embodiments, the biomarker is an antigen (e.g., TSH). In some embodiments, the capture site is an autoantibody (e.g., free autoantibody, complexed autoantibody) with specificity for the antigen (e.g., TSH).

[0104] In some embodiments, the interferent (which affects the measurement of thyroid stimulating hormone, free thyroxine, and free triiodothyronine) is macro-TSH, biotin, anti-streptavidin antibodies, anti-ruthenium antibodies, thyroid hormone autoantibodies, or heterophil antibodies.

[0105] (Cardiac function) The method described in some embodiments herein is used to evaluate cardiac function. Elevated circulating concentrations of troponin are biomarkers for cardiac disease, such as myocardial infarction. Cardiac I and T are specific indicators of myocardial damage. Subunits of troponin are also markers of cardiac health. In particular, cTnI and cTnT are biomarkers for acute myocardial infarction (AMI), such as type 1 and type 2 myocardial infarction, unstable angina, postoperative myocardial trauma, and related diseases. In some embodiments, the biomarker is free cTnI, free cTnT, binary cTnI-TnC, or ternary cTnI-TnC-TnT. In some embodiments, the biomarker is an indicator of heart failure. In some embodiments, the biomarker is an indicator of stroke (e.g., as described in https: / / www.ahajournals.org / doi / 10.1161 / STROKEAHA.117.017076 and https: / / www.360dx.com / business-news / roche-test-helps-differentiate-bleeding-risk-stroke-risk-patients-considering#.W1jz0thKhcA, which are incorporated by reference in their entireties). In some embodiments, the biomarker is an indicator of fibrosis (e.g., as described in http: / / www.onlinejacc.org / content / 65 / 22 / 2449, which are incorporated by reference in their entireties). In some embodiments, the biomarker is for the diagnosis of acute coronary syndrome (ACS). In some embodiments, the biomarkers are for cardiac troponin (I, IC, ICT, T) and other cardiac troponin fragments, natriuretic peptides (BNP, ANP, CNP), N-terminal fragments (e.g., NT-proBNP, NT-proCNP), glycosylated, non-glycosylated, CRP, myoglobin, creatine kinase (CK), CK-MB, sST2, GDF-15, and galectin-3.

[0106] In some embodiments, accuracy and precision can be improved by testing large sample volumes (i.e., 1 mL, 10 mL, 100 mL, 1000 mL, etc.), as well as very small sample volumes (i.e., neonatal, pediatric, elderly), samples that typically cannot be tested currently or require dilution of the sample prior to testing, reducing the sensitivity, accuracy, and precision of the test, to improve the detectability of very dilute or low concentrations of biomarkers. In some embodiments, the biological sample is 1 mL, 10 mL, 100 mL, 1000 mL, or even larger in volume. In some embodiments, the biological sample is 0.5 mL, 0.25 mL, 0.1 mL, 0.05 mL, or less in volume.

[0107] Also provided herein are methods for using pretreatment of particle samples prior to diagnostic testing to aid in the concentration of biomarkers by selectively releasing or eluting captured biomarkers, or capture site-biomarker complexes, from the particles after a washing step or particle separation prior to the biomarker characterization step or testing method.

[0108] As used herein, a "cleavage reagent" or "releasing agent" is an acidic or basic pH, high molar salt, sugar, chemical displacer, detergent, surfactant, and / or chelating agent, or combination thereof, that disrupts the binding of the biomarker to the capture site on the particle surface, e.g., displacing or eluting only the biomarker without displacing or eluting the capture site. After isolating the particles from the sample matrix by washing or magnet, the particles can be treated with an elution solution containing a releasing agent to selectively release the biomarker into solution. The particles can be rapidly (less than 2 minutes, ideally less than 30 seconds) isolated to the side and / or bottom of the sample device (vial, test tube, etc.), forming an essentially particle-free sample supernatant. The particle-free sample supernatant can then be aspirated without disrupting the particle-containing pellet, dispensed into another transfer tube, or directly into an analytical system (i.e., LC-MS / MS or MALDI-TOF) for testing the biomarker.

[0109] For example, the cleavage or release agents described herein may be used in a variety of elution buffers (e.g., pH increased with base such as sodium bicarbonate, pH decreased with acid such as acetic acid, trichloroacetic acid, sulfosalicylic acid, hydrochloric acid, formic acid, etc., elution buffers of common pH such as 100 mM glycine HCl at pH 2.5-3.0, 100 mM citric acid at pH 3.0, 50-100 mM triethylamine or triethanolamine at pH 11.5, 150 mM ammonium hydroxide at pH 10.5, etc.), displacers, - or displacement agents, competitive elution (e.g., counter-ligands or analogs at >0.1 M), ionic strength and / or chaotropic effects (e.g., NaCl, KCl, 3.5-4.0 M magnesium chloride in 10 mM Tris at pH 7.0, 5 M lithium chloride in 10 mL of phosphate buffer at pH 7.2, 2.5 M sodium iodide at pH 7.5, 0.2-3.0 M sodium thiocyanate), surfactants, detergents, concentrated inorganic salts, denaturing (e.g., 2-6 M guanidine HCl, Disrupt the binding interactions or cleavable bonds described herein between the particles described herein and the capture sites described herein using elution strategies such as elution with solvents such as 2-8 M urea, 1% deoxycholate, 1% SDS), organic solvents (e.g., alcohols, chloroform, ethanol, methanol, acetonitrile, hexane, DMSO, 10% dioxane, 50% ethylene glycol at pH 8-11.5 (also chaotropic), radiation or heat (high temperature), conformational changes, disulfide bond reducing agents (2-mercaptoethanol, dithiothreitol, tris(2-carboxyethyl)phosphine), enzyme inactivation, chaotropic agents (urea, guanidine chloride, lithium perchlorate), mechanical agitation, sonication, and protein digestive enzymes (pepsin, trypsin), and combinations thereof.

[0110] (Method of Characterization) Described herein are methods for depleting and / or enriching biomarkers for subsequent characterization or diagnostic testing. Characterization of a biomarker (e.g., an interferent) described herein includes identification and / or quantification of a biomarker (e.g., an interferent) described herein.

[0111] (Particles of the present invention) Described herein are particles for the isolation, depletion, and / or enrichment of biological samples. In some embodiments, the particles include a cleavable bond and a capture site (e.g., a particle surface functionalized to present one capture site). In some embodiments, the particles include a non-cleavable bond and a capture site (e.g., a particle surface functionalized to present one capture site). In some embodiments, the particles described herein include a capture site (e.g., a capture site with high specificity for a biomarker described herein). In some embodiments, the particles described herein (e.g., a surface of a particle described herein, a particle surface not bound to a capture site described herein) are inert (e.g., do not exhibit significant binding to a biomarker described herein). In some embodiments, the particles described herein can be used in the diagnostic tests described herein without further modification of the particle or the diagnostic test. In some embodiments, the particles described herein can be added to or removed from a sample without altering the sample (e.g., without adding or removing additional biomarkers (e.g., interferences)).

[0112] The particles described herein are sufficiently small, having an average diameter of 0.050 micrometers up to 3.00 micrometers, or preferably 0.100 micrometers to 1.1 micrometers in diameter, more preferably 0.200 micrometers to 0.600 micrometers, and even more preferably 0.100 micrometers to 0.500 micrometers in diameter.

[0113] In some embodiments, the particles (e.g., microparticles, nanoparticles) described herein include a core or support, which is a paramagnetic or superparamagnetic material selected from the group consisting of iron oxide, ferromagnetic iron oxide, Fe2O3, and Fe3O4, maghemite, or combinations thereof.

[0114] In some embodiments, the surface of the particle includes a hydrophobic organic polymer or copolymer. In some embodiments, the surface of a particle (e.g., nanoparticle, microparticle) includes an organic polymer or copolymer such as, but not limited to, a material selected from the group consisting of ceramic, glass, polymer, copolymer, metal, latex, silica, colloidal metal such as gold, silver, or alloy, polystyrene, derivatized polystyrene, poly(divinylbenzene), styrene acylate ester copolymers, styrene butadiene copolymers, styrene divinylbenzene copolymers, poly(styreneoxyethylene), polymethylmethacrylate, polymethacrylate, polyurethane, polyglutaraldehyde, polyethyleneimine, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, N,N'-methylenebisacrylamide, polyolefins, polyethylene, polypropylene, polyvinyl chloride, polyacrylonitrile, polysulfone, poly(ethersulfone), pyrolysates, block copolymers, and copolymers of the foregoing, silicone, or a biodegradable polymer such as silica, methylolmelamine, dextran, or poly(ethylene glycol) dextran (PEG-DEX), or a combination thereof.

[0115] As used herein, a "blocking agent" refers to a protein, a polymer, a surfactant, a detergent, or a combination thereof. In some embodiments, the binding of the capture site to the particles (e.g., nanoparticles, microparticles) described herein is blocked with a blocking agent, such as a protein, a polymer, a surfactant, a detergent, or a combination thereof. Blocking agents include proteins such as albumin, bovine serum albumin, human serum albumin, ovalbumin, gelatin, casein, acid hydrolyzed casein, gamma globulin, purified IgG, animal serum, polyclonal antibodies, and monoclonal antibodies; polymers such as polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP); combinations of proteins and polymers; peptides; PEGylation reagents such as (PEO)n-NHS or (PEO)n-maleimide; polymers such as triblock copolymers such as Pluronic® F108, F127, and F68; Triton X-100, polysorbate 20 (Tween-20), and Tween 100; The blocking agent is selected from the group consisting of non-ionic detergents such as 80 (non-ionic), zwitterionic detergents such as CHAPS, ionic detergents such as sodium dodecyl sulfate (SDS), deoxycholate, cholate, and sarkosyl, surfactants, sugars such as sucrose, and commercially available blocking agents such as Heterophile Blocking Reagent (Scantibodies), MAK33 (Roche Diagnostics), Immunoglobulin Inhibiting Reagent (IIR) (Bioreclamation), Heteroblock (Omega Biologicals), Blockmaster (JSR), TRU Block (Meridian Life Sciences), and StabilCoat® and StabilGuard® (Surmodics). In some embodiments, the blocking agent is bound (e.g., covalently, non-covalently) to the particles described herein. In some embodiments, the blocking agent is not bound (e.g., covalently, non-covalently) to the particles described herein.

[0116] (Cleavable bond) In one aspect, the capture site is attached to the biomarker by a cleavable bond as described herein. The cleavable bond can be made through a covalent bond or a non-covalent bond. Examples of non-covalent bonds include affinity, ionic, van der Waals (e.g., dipole / dipole or London forces), hydrogen bonds (e.g., between polynucleotide duplexes), and hydrophobic interactions. When the bond is a non-covalent bond, the bond between the entities is preferably specific. Non-limiting examples of specific non-covalent binding include binding interactions between biotin and a biotin-binding protein such as avidin, captavidin, SA, neutravidin, a fragment of SA, a fragment of avidin, a fragment of neutravidin, or mixtures thereof; binding of a biotinylated Fab, a biotinylated immunoglobulin or a fragment thereof, a biotinylated small molecule (e.g., a ligand for a hormone or receptor), a biotinylated polynucleotide, a biotinylated macromolecule (e.g., a protein, or a natural or synthetic polymer) to a biotin-binding protein such as avidin, SA, neutravidin, a fragment of SA, a fragment of avidin, a fragment of neutravidin, or mixtures thereof; binding of a substrate to an enzyme; binding of a glycoprotein to a lectin specific for the glycoprotein; binding of a ligand to a receptor specific for the ligand; binding of an antibody to an antigen against which the antibody is raised; and duplex formation between a polynucleotide and a complementary or substantially complementary polynucleotide.

[0117] A cleavable bond such as a disulfide bond (RSSR) is used to immobilize or capture the capture site (i.e., an antibody or antibody fragment such as SH-Fab) to the particle. After washing or isolating the particles from the sample matrix, the particles can be treated with a solution containing a reducing agent such as TCEP or DTT to cleave the disulfide bond and release the capture site-biomarker complex into solution. The particles can be rapidly (less than 2 minutes, ideally less than 30 seconds) isolated to the side and / or bottom of the sample device (vial, test tube, etc.) to form an essentially particle-free sample supernatant. The particle-free sample supernatant can then be aspirated without disturbing the particle-containing pellet and dispensed into another transfer tube or placed directly into an analytical system (i.e., LC-MS / MS or MALDI-TOF, or molecular diagnostics such as FilmArray blood culture panels) to test for the capture site-biomarker complex.

[0118] In some embodiments, the cleavable bond is a disulfide bond (RSSR).

[0119] In some embodiments, the cleavable bond is a non-covalent bond between streptavidin, captavidin, or avidin and biotin.

[0120] (Capturing site) Described herein is a particle that comprises one kind of capture site that binds to an interfering substance as described herein or a biomarker as described herein.As described herein, the "capture site" is selected from the group consisting of antibody, antibody binding fragment, IgG, IgM, IgA, IgE, IgD, receptor, receptor ligand, hormone, hormone receptor, enzyme, enzyme substrate, single-stranded oligonucleotide, single-stranded polynucleotide, double-stranded oligonucleotide, double-stranded polynucleotide, antigen, peptide, polymer, aptamer, and protein.

[0121] In some embodiments, the capture site is a protein. The protein can be, for example, a monomer, dimer, multimer, or fusion protein. In certain embodiments, the protein includes at least one albumin or mixtures thereof, such as, for example, an antibody, a fragment of an antibody, BSA, ovalbumin, a fragment of BSA, a fragment of ovalbumin, mouse IgG, polymerized mouse IgG, antibody fragments (Fc, Fab, F(ab')2) and different subclasses of mouse IgG (IgG1, IgG2a, IgG2b, IgG3, IgE, IgD) against targeting HAMA and RF interference mechanisms, purified animal polyclonal antibodies (i.e., cow, goat, mouse, rabbit, sheep) against targeting HAAA interference, streptavidin, ALP, HRP, BSA (conjugated with isoluminol, ruthenium, acridinium) against targeting MASI interference.

[0122] In some embodiments, the capture moiety is a human anti-animal antibody (eg, mouse IgG, sheep IgG, goat IgG, rabbit IgG, bovine IgG, porcine IgG, horse IgG). In some embodiments, the capture site is a heterophile antibody (e.g., FR (Fc specific), Fab, F(ab)'2, polymerized IgG (type 1, 2a, 2b IgG and IgG fragments, serum components). In some embodiments, the capture site is an assay-specific binding agent (e.g., biotin, fluorescein, anti-fluorescein poly / Mab, anti-biotin poly / Mab, streptavidin, neutravidin). In some embodiments, the capture site is an assay-specific single molecule (e.g., HPR, ALP, acridinium ester, isoluminol / luminol, ruthenium, ABEI / cyclic ABEI). In some embodiments, the capture site is an assay-specific blocking agent (e.g., BSA, fish skin gelatin, casein, ovalbumin, PVP, PVA). In some embodiments, the capture site is an assay-specific binding linker (e.g., LC, LC-LC, PEO4, PEO16). In some embodiments, the capture moiety is an antigen autoantibody (e.g., free T3, free T4). In some embodiments, the capture moiety is a protein autoantibody (e.g., MTSH, TnI, TnT, non-cardiac TnT (skeletal muscle disease)). In some embodiments, the capture moiety is a chemiluminescent substrate (e.g., luminol, isoluminol, isoluminol derivatives, ABEI, ABEI derivatives, ruthenium, acridinium esters), or a fluorescent label (e.g., fluorescein or other fluorophores, and stains). In some embodiments, the capture moiety is streptavidin, neutravidin, avidin, polyA, polyDT, aptamer, antibody, Fab, F(ab)'2, antibody fragment, recombinant protein, enzyme, protein, biomolecule, polymer, or molecularly imprinted polymer. In some embodiments, the capture moiety is biotin, fluorescein, polyDT, polyA, antigen, etc.

[0123] In some embodiments, the capture site binds to biotin (eg, avidin, streptavidin, neutravidin, captavidin, anti-biotin antibodies, antibody fragments, aptamers, molecularly imprinted polymers, etc.).

[0124] In at least one embodiment, the present invention provides a binding surface with two or more different capture sites.

[0125] (Generation of capture sites) In one aspect, provided is a method of producing a capture site that involves producing or generating a complex-specific or structure-specific antibody against a free autoantibody or an autoantibody complex. A free autoantibody is an autoantibody that is not yet complexed with an antigen target. A complex autoantibody is an autoantibody that is complexed with an antigen target.

[0126] In one aspect, provided is a method of producing a capture site, comprising producing or generating a complex-specific or structure-specific antibody against an autoantibody complex, such as MTSH. In some embodiments, the autoantibody is triiodothyronine (T3) or thyroxine (T4). In some embodiments, the autoantibody complex is MTSH. For example, a complex-specific or structure-specific antibody can be produced to an autoantibody complex, such as MTSH, purified from human serum, and used as a capture site. In this manner, the antibody will only have specificity for the complex of hIgG or hIgM with TSH. MTSH can be purified based on technology and published methods, or by those skilled in the art of protein biochemistry and purification. In some embodiments, autoimmune disease patients who are most likely to interfere with autoantibody assays are used to produce or generate the autoantibodies. See, for example, HyTest SES Assay for BNP in WO2014114780, WO2016113719, and WO2016113720, the references being cited in their entireties.

[0127] (Thyroid-specific antibodies) For example, in certain embodiments, the autoantibody is an anti-thyroid autoantibody (anti-thyroid peroxidase antibody, thyrotropin receptor antibody, thyroglobulin antibody). Anti-thyroid autoantibodies are autoantibody targets that are directed against one or more components of the thyroid gland.

[0128] In some embodiments, the autoantibody is a free autoantibody (eg, thyrotropin (TSH)).

[0129] In some embodiments, the autoantibody is a composite autoantibody (e.g., MTSH). In some embodiments, the capture moieties described herein are antibodies generated with specificity for composite autoantibodies or with structural specificity for hIgG and / or hIgM already bound to an antigen target such as MTSH.

[0130] Below is a non-limiting list of substances that can function as one or the other member of a binding pair consisting of an analyte binder (capture site) and an analyte, depending on the application for which the affinity assay is designed. Such substances can be used, for example, as capture sites (analyte binders) or can be used to generate capture sites that can be used in the present invention (e.g., by use as haptens / antigens to generate specific antibodies). Affinity assays, including immunoassays, can be designed according to the present invention to detect the presence and / or concentration of such substances as analytes in a sample. In certain embodiments, the capture sites of the present invention that bind to analytes can be used to detect these substances as analytes in a sample. Alternatively, the substances listed below can be associated with a solid support surface according to the present invention and used to capture capture molecules that interact with them (e.g., antibodies or fragments thereof, binding proteins, or enzymes specific for the listed substances, etc.).

[0131] A non-limiting list of substances that may function as one member or the other of a binding pair consisting of an analyte binder (capture site) and an analyte includes inducible nitric oxide synthase (iNOS), CA19-9, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-t, IL-5, IL-7, IL-10, IL-12, IL-13, sIL-2R, sIL-4R, sIL-6R, SIV core antigen, IL-1RA, TNF-α, IFN-gamma, GM-CSF; PSA, pPSA, B PSA (prostate specific antigen) such as PSA, inPSA, non-α1 antichymotrypsin complexed PSA, α1 antichymotrypsin complexed PSA, isoforms of prostatic kallikrein such as hK2, hK4, and hK15, ek-rhK2, Ala-rhK2, TWT-rhK2, Xa-rhK2, HWT-rhK2, and other kallikreins; HIV-1p24; ferritin, L-ferritin, troponin I, BNP, leptin, digoxin, myoglobin, B-type natriuretic peptide, or brain natriuretic peptide. Peptides (BNP), N-terminal pro-BNP, CNP, N-terminal pro-CNP(1-50), N-terminal CNP-53(51-81), CNP-22(82-103), CNP-53(51-103), atrial natriuretic peptide (ANP); human growth hormone, bone alkaline phosphatase, human follicle-stimulating hormone, human luteinizing hormone, prolactin; human chorionic gonadotrophin (e.g., CGα, CGβ); soluble ST2, thyroglobulin; anti-thyroglobulin; IgE, IgG, IgG1 , IgG2, IgG3, IgG4, B. anthracis protective antigen, B. anthracis lethal factor, B. anthracis spore antigen, F. tularensis LPS, S. aureus enterotoxin B, Y. pestis capsular F1 antigen, insulin, alpha-fetoprotein (e.g., AFP300), carcinoembryonic antigen (CEA), CA15.3 antigen, CA19.9 antigen, CA125 antigen, HAV Ab, HAV Igm, HBc Ab, HBc Igm, HIV1 / 2, HBsAg, HBsAb, HCVAb, anti-p53, histamine; neopterin; s-VCAM-1, serotonin, sFas, sFas ligand, sGM-CSFR, s1CAM-1, thymidine kinase, IgE, EPO, intrinsic factor Ab, haptoglobulin, anticardiolipin, anti-dsDNA, anti-Ro, Ro, anti-La, anti-SM, SM, anti-nRNP, anti-histone, anti-Scl-70, Scl-70, antinuclear antibody, anticentromere antibody, SS-A, SS-B, Sm, U1-RNP, Jo-1, CK, CK-MB, CRP, ischemia-modified albumin, HDL, LDL, oxLDL, VLDL, troponin T, troponin I, troponin C, microalbumin, amylase, ALP, ALT, AST, GGT, IgA, IgG, prealbumin, antistreptolysin, chlamydia, CMVIgG, toxo-IgG, toxo-IgM, apolipoprotein A, apolipoprotein B, C3, C4, properdin factor B, albumin, α1-acid glycoprotein, α1-antitrypsin, α1-microglobulin, α2-microglobulin, antistreptolysin-O, antithrombin III, apolipoprotein A1, apolipoprotein B, β2-microglobulin, ceruloplasmin, complement component C3, complement component C4, C-reactive protein, DNase B, ferritin, free Kappa light chain, free lambda light chain, haptoglobin, immunoglobulin A, immunoglobulin A (CSF), immunoglobulin E, immunoglobulin G, immunoglobulin G (CSF), immunoglobulin G (urine), immunoglobulin G subclasses, immunoglobulin M, immunoglobulin M (CSF), kappa light chain, lambda light chain, lipoprotein(a), microalbumin, prealbumin, properdin factor B, rheumatoid factor, ferritin, transferrin, transferrin (urine), rubella IgG, thyroglobulin Phosphoantibody, Toxoplasma IgM, Toxoplasma IgG, IGF-I, IGF-binding protein (IGFBP)-3, hepsin, pim1 kinase, E-cadherin, EZH2, a-methylacyl-CoA racemase, TGF-beta, IL6SR, GAD, IA-2, CD-64, neutrophil CD-64, CD-20, CD-33, CD-52, cytochrome P450 isoforms, s-VCAM-1, sFas, sICAM, hepatitis B surface antigen, thromboplastin, HIVp24, HIVgp41 / 1 These include 20, HCVC22, HCVC33, hemoglobin A1c, GAD65, IA2, vitamin D, 25-OH vitamin D, 1,25(OH)2 vitamin D, 24,25(OH)2 vitamin D, 25,26(OH)2 vitamin D, the 3-epimer of vitamin D, FGF23, sclerostin, procalcitonin, calcitonin, Clostridioides difficile toxins A and B, Helicobacter pylori, HSV1, and HSV2.

[0132] Depending on the application for which the affinity assay is designed, suitable materials that may function as one member of a binding pair consisting of an analyte binder (capture moiety) and an analyte or the other member and that may be used in the present invention include moieties specific for any of the WHO International Biological Reference Materials (updated June 30, 2005, listing materials well known in the art and available at http: / / www.who.int / bloodproducts / re_materials, which is incorporated herein by reference), such as, for example, antibodies or fragments thereof, that are maintained, characterized and / or distributed by the WHO International Laboratory for Biological Standards.

[0133] A partial list of such appropriate international standards, identified by the WHO code in parentheses following the substance, includes: recombinant human thromboplastin (rTF / 95), rabbit thromboplastin (RBT / 90), thyroid stimulating antibody (90 / 672), recombinant human tissue plasminogen activator (98 / 714), high molecular weight urokinase (87 / 594), prostate specific antibody (96 / 668), prostate specific antibody 90:10 (96 / 7 00; human plasma protein C (86 / 622), human plasma protein S (93 / 590), rheumatoid arthritis serum (W1066), serum amyloid A protein (92 / 680), streptokinase (00 / 464), human thrombin (01 / 580), bovine combined thromboplastin (OBT / 79), anti-D positive control intravenous immunoglobulin (02 / 228), islet cell antibody (97 / 550), lipoprotein a (IFCC SRM2B), human parvovirus B19 DNA (99 / 800), human plasmin (97 / 536), human plasminogen activator inhibitor 1 (92 / 654), platelet factor 4 (83 / 505), prekallikrein activator (82 / 530), human brain CJD control and human brain sporadic CJD preparation 1 and human brain sporadic CJD preparation 2 and human brain variant CJD (none; WHO TRS, respectively). ECBS Report No. 926, cited in 53sup.rd Report, Brain Homogenate), human serum complement components including C1q, C4, C5, factor B, and full-function complement CH50 (W1032), human serum immunoglobulin E (75 / 502), human serum immunoglobulin G, A, and M (67 / 86), human serum proteins albumin, alpha 1-antitrypsin, alpha 2-macroglobulin, ceruloplasmin, complement component C3, transferrin (W1031), anti-D negative control intravenous immunoglobulin (02 / 226), hepatitis A RNA (00 / 560), hepatitis B surface antigen subtype adw2 genotype A (03 / 262 and 00 / 588), hepatitis B virus DNA (97 / 746), hepatitis C virus RNA (96 / 798), HIV-1 p24 antigen (90 / 636), HIV-1 RNA (97 / 656), HIV-1 RNA genotype (set of 10 I01 / 466), human fibrinogen concentrate (98 / 614),Human plasma fibrinogen (98 / 612), elevated A2 hemoglobin (89 / 666), elevated F hemoglobin (85 / 616), hemoglobin cyanide (98 / 708), low molecular weight heparin (85 / 600 and 90 / 686), unfractionated heparin (97 / 578), blood clotting factor VIII and von Willebrand factor (02 / 150), human blood clotting factor VIII concentrate (99 / 678), human blood clotting factor XIII plasma (02 / 206), human blood clotting factors II, VII, IX, X (99 / 826), human blood clotting factor II and X concentrate (9 8 / 590), human carcinoembryonic antigen (73 / 601), human C-reactive protein (85 / 506), recombinant human ferritin (94 / 572), apolipoprotein B (SP3-07), beta 2 microglobulin (B2M), human beta thromboglobulin (83 / 501), human blood coagulation factor IX concentrate (96 / 854), human blood coagulation factor IXa concentrate (97 / 562), human blood coagulation factor V Leiden, human gDNA samples FV wild type, FVL homozygote, FVL heterozygote (03 / 254, 03 / 260, 03 / 248), human blood coagulation factor VII concentrate (97 / 592), human blood coagulation factor VIIa concentrate (89 / 688), human antisyphilis serum (HS), human anti-tetanus immunoglobulin (TE-3), human antithrombin concentrate (96 / 520), human plasma antithrombin (93 / 768), human antithyroglobulin serum (65 / 93), anti-toxoplasma serum (TOXM), human anti-toxoplasma serum (IgG) (01 / 600), human anti-varicella zoster immunoglobulin (W1044), apolipoprotein A-1 (SP1-01), human anti-interferon beta serum (G038-501-572 ), human anti-measles serum (66 / 202), anti-nuclear ribonucleoprotein serum (W1063), anti-nuclear factor (homogeneous) serum (66 / 233), anti-parvovirus B19 (IgG) serum (91 / 602), anti-parvovirus types 1, 2, and 3 serum (66 / 202), human anti-rabies immunoglobulin (RAI), human anti-rubella immunoglobulin (RUBI-1-94), anti-smooth muscle serum (W1062), human anti-double-stranded DNA serum (Wo / 80), human anti-E complete blood group serum (W1005), human anti-Echinococcus serum (ECHS), human anti-hepatitis A immunoglobulin (97 / 646),These include human anti-hepatitis B immunoglobulin (W1042), human anti-hepatitis E serum (95 / 584), anti-human platelet antigen 1a (93 / 710), anti-human platelet antigen 5b (99 / 666), human anti-interferon alpha serum (B037-501-572), human alpha fetoprotein (AFP), ancrod (74 / 581), human anti-A blood grouping serum (W1001), human anti-B blood grouping serum (W1002), human anti-C complete blood grouping serum (W1004), anti-D (anti-Rh0) complete blood grouping serum (99 / 836), human anti-D (anti-Rh0) incomplete blood grouping serum (W1006), and human anti-D immunoglobulin (01 / 572).

[0134] Other examples of suitable substances that may function as one or the other member of a binding pair consisting of an analyte binder (capture site) and an analyte depending on the application for which the affinity assay is designed include compounds that can be used as haptens to generate antibodies capable of recognizing the compounds, including but not limited to the following: hormones, including but not limited to progesterone, estrogens, testosterone, progestins, corticosteroids, and dehydroepiandrosterone, and any salts, esters, or ethers of non-protein / non-polypeptide antigens listed as international reference standards by the WHO. A partial list of such suitable international reference standards, identified by the WHO code in parentheses following the substance, includes vitamin B12 (WHO81.563), folate (WHO95 / 528), homocysteine, transcobalamin, T4 / T3, and other substances listed in the WHO Catalogue of International Biological Reference Materials (available on the WHO web, e.g., at http: / / www.who.int / bloodproducts / ref_materials / , updated June 30, 2005), which is incorporated herein by reference. The methods and compositions described herein can include the aforementioned WHO reference standards or mixtures containing the reference standards.

[0135] Other examples of substances that may function as one or the other member of a binding pair consisting of an analyte binding agent (capture site) and an analyte, depending on the application for which the affinity assay is designed, include drugs of abuse.Drugs of abuse include, for example, the following list of medications: heroin, morphine, hydromorphone, codeine, oxycodone, hydrocodone, fentanyl, Demerol, methadone, Darvon, Stadol, Talwin, Paregoric, Buprenex; stimulants such as amphetamine, methamphetamine; methylamphetamine, ethylamphetamine, methylphenidate, ephedrine, pseudoephedrine, ephedra, ephedra, methylenedioxyamphetamine (MDS), phentermine, phenylpropanolamine; amiphenazole, bemiphenazole, Glyde, benzphetamine, bromethane, chlorphentermine, clopropamide, crotethamide, diethylpropion, dimethylamphetamine, doxapram, etamivan, fencamfamine, meclofenoxate, methylphenidate, nikethamide, pemoline, pentetrazole, phendimetrazine, phenmetrazine, phentermine, phenylpropanolamine, picrotoxin, pipradol, prolintane, strychnine, synephrine, phencyclidine, and analogs such as angel dust, PCP, ketamine, and the like; e.g., barbiturates, Antidepressants such as tulose, glutethimide, methaqualone, and meprobamate, methohexital, thiamyl, thiopental, amobarbital, pentobarbital, secobarbital, butalbital, butabarbital, talbutal, and aprobarbital, phenobarbital, mephobarbital; for example, estazolam, flurazepam, temazepam, triazolam, midazolam, alprazolam, chlordiazepoxide, clorazepate, diazepam, halazepam, lorazepam, oxazepam, prazepam, quazepam, clonazepam. , benzodiazapenes such as flunitrazepam; GBH drugs such as gamma hydroxylbutyric acid and gamma butyrolactone; glutethimide, methaqualone, meprobamate, carisoprodol, zolpidem, zaleplon; cannabinoid drugs such as tetrahydracannabinol and analogues; cocaine, 3-4 methylenedioxymethamphetamine (MDMA); hallucinogens such as mescaline and LSD, as well as their metabolites (e.g., metabolites present in blood, urine, and other biological materials), and any salts, esters, or ethers thereof.

[0136] (Example) Example 1: Depletion of biotin interference after high doses of biotin intake Endogenous (non-spiked) biotin samples were collected serially. Baseline serum samples were collected from five apparently healthy adult volunteers (four males, one female) by subconjunctival venous blood draw using BD brand Vacutainer™ 10 mL red top tubes. Each volunteer then received a 20 mg dose of biotin (4 x 5 mg, Finest Nutrition Biotin 5000 mcg Strawberry, fast dissolving, product number 938508, sold by Walgreens). Serum samples were collected at 1, 3, 6, 8, and 24 hours after biotin ingestion. Blood was allowed to clot for 1 hour at RT and centrifuged at 2000 rpm for 15 minutes in a Beckman Allegra 6R tabletop centrifuge. For each time point, serum samples from each volunteer were pooled, mixed for 15 min at RT, dispensed into 1.2 mL aliquots in 2 mL cryovials, and frozen at -80°C.

[0137] Biotin metabolites were determined by measuring biotin concentration in consecutively collected samples using a free biotin ELISA. Biotin serum samples were tested with Immundiagnostik's IDK® Biotin ELISA kit (part number K8141, lot number 180906, measuring range 48.1-1100 pg / mL). Samples exceeding the kit's measurement range were diluted with the kit's sample dilution buffer. Samples collected 1, 3, 6, and 8 hours after biotin ingestion were assumed to be in the range of 50,000-500,000 pg / mL and were diluted 1:1000. Samples collected 24 hours after biotin ingestion were assumed to be near or below 20,000 pg / mL and were diluted 1:20. Samples were tested according to the ELISA kit protocol, and biotin concentrations were still significantly elevated 8 hours (60–107 ng / mL, n = 5) and 24 hours (24–32 ng / mL, n = 4) after ingestion of 20 mg biotin.

[0138] [Table 1]

[0139] High concentrations of endogenous biotin (370 or 550 ng / mL) were depleted from serially collected serum samples using streptavidin-coated superparamagnetic nanoparticles (VERAPREP Biotin Reagent) by adding 200 μL of serum to a 1.5 mL microcentrifuge tube, adding 20 μL of VERAPREP Biotin Reagent, gently mixing / rocking the sample for 10 minutes, magnetically separating the VERAPREP Biotin Reagent using a Dexter LifeSep® 1.5S for 10 minutes, aspirating the serum carefully to avoid disturbing the magnetic particles, and testing the serum samples using a free biotin ELISA.

[0140] In the first study, increasing amounts (mg) of VERAPREP Biotin reagent were added to different aliquots of the same high concentration biotin (370ng / mL) endogenous serum samples to determine the amount of reagent required to 100% deplete free biotin in the samples. 20μL of VERAPREP Biotin reagent (230nm diameter, 32μg streptavidin per mg beads) was added to each 200μL aliquot of serum collected 1 hour after ingesting 20mg biotin, mixed by gentle end-over-end mixing for 10 minutes at room temperature, and magnetically separated using a Dexter LifeSep1.5S magnet for 10 minutes. 175μL of serum supernatant was carefully aspirated and measured using the Immundiagnostik IDK® Biotin ELISA kit (part number K8141, lot number 180906), and samples exceeding the measuring range of the kit were diluted with the kit's sample dilution buffer. VERAPREP Biotin reagent at 230 nm successfully depleted 100% of free biotin using a simple 20 min step, 200 μL of sample, and only 0.39 mg reagent (Figure 5).

[0141] In the second study, increasing amounts (in mg) of two different VERAPREP Biotin reagents were added to different aliquots of the same high concentration biotin (550 ng / mL) serum sample to determine the amount of each reagent required to deplete 100% of the free biotin in the sample. 20 μL of 230 nm VERAPREP Biotin reagent (32 μg streptavidin per mg beads) or 20 μL of 550 nm VERAPREP Biotin reagent (4 μg streptavidin per mg beads) were added to each 200 μL aliquot of serum sample collected 1 hour after 50 mg biotin intake, mixed by gentle end-over-end mixing for 10 minutes at room temperature, and magnetically separated using a Dexter LifeSep 1.5S magnet for 10 minutes. 175 μL of serum supernatant was carefully aspirated and measured by Immundiagnostik IDK® Biotin ELISA kit (part number K8141, lot number 180906), and samples exceeding the measurement range of the kit were diluted with the kit's sample dilution buffer. VERAPREP Biotin Reagent at 230 nm successfully depleted 100% of free biotin using a simple 20-minute process, 200 μL of sample, and only 0.75 mg reagent, while VERAPREP Biotin Reagent at 550 nm only depleted 89% of free biotin with 1.86 mg reagent. These results indicate that the binding capacity and binding efficiency of VERAPREP Biotin Reagent can be improved by increasing the surface area per unit volume with smaller bead diameters, increasing the amount of streptavidin and biotin binding capacity per mg of beads, and / or increasing the concentration or amount (mg) of VERAPREP Biotin Reagent (Figure 6).

[0142] Example 2: Biotin interference depletion using a sample pretreatment reagent optimized to bind and deplete high concentrations of free biotin in serum samples. Six volunteers (five apparently healthy adults aged 25-46 years and one with type 2 diabetes aged 65 years) had baseline fasting serum samples collected by pre-anal vein blood draw into BD brand Vacutainer™ 10 mL red top tubes. Each volunteer then received 20 mg, 100 mg, or 200 mg of over-the-counter (OTC) biotin. For the 20 mg dose, serum samples were collected 1, 3, 6, 8, and 24 hours after biotin ingestion. For the 100 and 200 mg doses, serum samples were collected 1, 6, and 24 hours after biotin ingestion. Blood was allowed to clot for 1 hour at RT and centrifuged at 2000 rpm for 15 minutes in a Beckman Allegra 6R tabletop centrifuge. For each time point and each biotin dose, serum samples from each volunteer were pooled, mixed for 15 min at RT, dispensed into 1.2 mL aliquots in 2 mL cryovials, and frozen at -80 °C. All samples were sent to the University of Washington, School of Laboratory Medicine, 1959 Pacific Street NE, Seattle, WA 98195, for biotin measurement by LC-MS / MS. At the 20 mg dose, biotin concentrations were highest at 1 hour (96–179 ng / mL), at 6 hours serum biotin concentrations in all five volunteers were still above 15 ng / mL (17–35), at 8 hours plasma biotin concentrations in four of the five volunteers were above 15 ng / mL (16–28), and at 24 hours biotin concentration in volunteer 1 with known type 2 diabetes was above 15 ng / mL (18) (Figure 7).

[0143] For the 100 and 200 mg doses, biotin concentrations were highest at 1 hour, ranging from 294 to 459 ng / mL for the 100 mg dose and 610 to 861 ng / mL for the 200 mg dose. At 6 hours, serum biotin concentrations in volunteers who received either 20 mg or 100 mg biotin were greater than 15 ng / mL, ranging from 17 to 35 ng / mL for the 20 mg dose, and 95 to 347 ng / mL for the 200 mg dose. At 24 hours, two volunteers who received 100 mg biotin had biotin concentrations greater than 15 ng / mL, volunteer 1 with known diabetes had a biotin concentration of 84 ng / mL, and volunteer 6 had a biotin concentration of 54 ng / mL (Figure 8).

[0144] Four samples were selected as having high endogenous biotin concentrations (294-861ng / mL) and were measured by LC-MS / MS (Figure 9). Baseline serum samples were tested by PTH Intact ELISA (DRG PTH Intact ELISA, part number EIA-3645) and PTH results ranged from 28.1pg / mL to 50.3pg / mL. PTH in all samples 1 hour after biotin ingestion was below 1.57pg / mL or below the lower limit of detection (LLD) (Figure 10).

[0145] All four samples were pretreated with optimized 550 nm superparamagnetic nanoparticles (VeraPrep Biotin) coated with streptavidin. Samples 1 and 4, which had biotin concentrations <500 ng / mL by LC-MS / MS, were pretreated with 0.5 mL of reagent, and samples 2 and 3, which had biotin concentrations >500 ng / mL by LC-MS / MS, were pretreated with 1.5 mL of reagent, using the following protocol: 1. Remove the VERAPREP Biotin vial from storage and vortex at medium speed for a minimum of 10 seconds to mix well and resuspend the reagent. 2. Insert the reagent vial into the foam vial holder. 3. Insert an empty 2ml microcentrifuge tube (SARSEDT, order number 72.694) into the LifeSep® 1.5S magnet until the neck of the tube touches the magnetic frame. 4. Dispense 200 μL (0.5 mg) or 600 μL (1.5 mg) of the well-mixed reagent into an empty tube and separate the reagent on a magnet for ≥30 s to form a reagent pellet. 5. Carefully aspirate and discard all storage buffer supernatant (~200 μL or ~600 μL) without disturbing the reagent pellet. 6. Dispense 400 μL of well-mixed serum or plasma sample into the tube containing the reagent pellet. 7. Screw the cap on the tube, remove the tube from the magnet, and vortex at medium speed for at least 10 seconds to mix well and resuspend the reagent in the sample. 8. Place the tube on a laboratory mixer at medium speed and incubate at room temperature for 10 minutes. 9. Loosen the screw cap and insert the tube into the magnet until the neck of the tube touches the magnet frame. 10. Magnetically separate the reagents for >4 minutes to form a reagent pellet. 11. Carefully aspirate the sample supernatant without disturbing the reagent pellet and dispense the sample into a transfer tube for testing. NOTE: If this step is performed carefully, it is possible to aspirate all of the sample supernatant (approximately 400 μL). If reagent is accidentally aspirated, simply pour the sample / reagent mixture back into the tube and return to step 10. 12. The sample is ready for testing.

[0146] To ensure that biotin interference was removed, samples pretreated with VeraPrep Biotin were tested using Immundiagnostik's IDK® Biotin ELISA kit (part number K8141, measures a range of 48.1-1,100 ng / L). Biotin concentrations ranged from 0.2-1.0 ng / mL, or within normal plasma concentrations (200-1,200 ng / L) (Figure 9). PTH levels were measured using the PTH Intact ELISA immediately after pretreatment of samples 1-4 with VeraPrep Biotin, and PTH values ​​ranged from 26.7-52.0 pg / mL (Figure 10).

[0147] Samples taken 1 hour after biotin ingestion had high levels of biotin interference (294-861 ng / mL) by LC-MS / MS and undetectable PTH values ​​(<1.57 pg / mL) by PTH Intact ELISA, whereas samples taken 1 hour after biotin ingestion pretreated with VeraPrep Biotin showed physiologically normal biotin values ​​(<1.1 ng / mL) by the biotin ELISA kit and normal PTH values ​​(26.7-52.0 pg / mL) by PTH Intact ELISA (Figures 9 and 10). Comparing the PTH values ​​of samples pretreated with VeraPrep Biotin to baseline PTH values, results showed a range of 95%-113% recovery (average 105% recovery) (Figure 10). Significant differences in test results after sample pretreatment with VeraPrep Biotin or significant increases in PTH values ​​in the PTH Intact ELISA sandwich immunoassay confirmed that biotin interference was clinically significant in all four samples tested.

[0148] Example 3: Small Volume Biomarker Concentration Very low concentrations of biomarkers (0.0195 μIU TSH / mL or 0.497 pg PTH / mL) in 40 mL of PBS were concentrated using 550 nm superparamagnetic nanoparticles coated with streptavidin and then coated with biotinylated anti-TSH antibody (VERAPREP Concentrate TSH Reagent) or biotinylated anti-PTH monoclonal antibody (VERAPREP Concentrate PTH Reagent).

[0149] In the first study, VERAPREP Concentrate TSH reagent was prepared by coating 550 nm VERAPREP Biotin with biotinylated anti-TSH capture antibody. 0.08 mL of TSH antigen (10 μIU / mL, for ELISA calibration) was diluted with 41 mL PBS buffer to 0.0195 μIU / mL, which is below the functional sensitivity (<0.054 μIU / mL) of the DRG TSH Ultrasensitive ELISA (Part No. EIA-1790, Lot No. RN58849), and 1 mL was saved as a baseline sample (before concentration). 40 mL of the sample was processed using the VERAPREP Concentrate TSH protocol to produce 1.0 mL of concentrated sample for subsequent TSH ELISA testing.

[0150] Dilute 80 µL of the 10 µIU / mL TSH standard solution to 0.0195 µIU / mL in 41.0 mL of PBS and save 1.0 mL as a baseline sample (before concentration). 1. Dilute 80 μL of 10 μIU / mL TSH standard solution with 1.0 mL of VERAPREP Cleave as Control to 0.80 μIU / mL. 2. Add 40 μL of 0.0196 μIU / mL TSH in PBS to a 50 mL Falcon tube. 3. Add VERAPREP Concentrate TSH mixture. 4. Incubate at room temperature for 60 minutes with mixing. 5. Magnetically separate VERAPREP Concentrate TSH using a Dexter LifeSep® 50SX for 60 minutes. 6. Decant and discard 40 mL of PBS. 7. Add 4.0 mL of PBS wash buffer and mix. 8. Magnetically separate VERAPREP Concentrate TSH in 4 mL PBS wash buffer using a Dexter LifeSep® 50SX for 30 minutes. 9. Decant and discard 4 mL of PBS. 10. Add 1 mL of PBS wash buffer and mix. 11. Transfer 1 mL of VERAPREP Concentrate TSH to a 1.75 mL conical bottom snap cap vial. 12. Magnetically separate VERAPREP Concentrate TSH in 1 mL PBS wash buffer using a Dexter LifeSep® 1.5S for 10 minutes. 13. Aspirate and discard 1 mL of PBS. 14. Add 1 mL of VERAPREP Cleave and mix. 15. Magnetically separate VERAPREP Concentrate TSH in 1 mL VERAPREP Cleave using Dexter LifeSep® 1.5S for 10 minutes. 16. 1 mL of the supernatant (concentrated sample) was aspirated and saved to test the control, baseline, and concentrated samples.

[0151] 0.08 mL of TSH antigen (10 μIU / mL, for ELISA calibration) was also diluted to 0.800 μIU / mL with 1 mL of VERAPREP Cleave buffer as a control. The baseline sample, concentrated sample, and control were measured by DRG TSH Ultrasensitive ELISA, and the TSH recovery rate of the concentrated sample was calculated as [concentrated sample result] / [control result] × 100%. As expected, the diluted TSH baseline sample was not detected by Ultrasensitive ELISA and displayed as 0.00 μIU / mL. Using only 0.80 mg of reagent, VERAPREP Concentrate TSH successfully concentrated the diluted TSH from undetectable to 0.73 μIU / mL (Table 2). Although the recovery rate was 98.6% compared to the control, the matrix effect of VERAPREP Cleave buffer in the TSH ELISA may have suppressed the assay signal (Table 3).

[0152] [Table 2]

[0153] [Table 3]

[0154] In the second study, VERAPREP Concentrate PTH reagent was prepared by coating 550 nm VERAPREP Biotin with biotinylated anti-PTH capture sites. 0.021 mL of PTH antigen (971 pg / mL, for ELISA calibration) was also diluted to 0.497 pg / mL in 41 mL PBS buffer, below the functional sensitivity (<1.56 pg / mL) of the DRG PTH (Parathyroid) Intact ELISA (Part No. EIA-3645, Lot No. 2896), and 1 mL was saved as a baseline sample (before concentration). The 40 mL sample was processed using the VERAPREP Concentrate PTH protocol to produce a 1.0 mL concentrated sample for subsequent PTH ELISA testing. 1. Dilute 21 µL of 971 pg / mL PTH standard solution to 0.497 pg / mL in 41.0 mL of PBS and save 1.0 mL as a baseline sample (before concentration). 2. Dilute 21 μL of 971 pg / mL PTH standard solution to 20.4 pg / mL with 1.0 mL of VERAPREP Cleave as a control. 3. Add 40 mL of 0.497 pg / mL PTH in PBS to a 50 mL Falcon tube. 4. Add VERAPREP Concentrate PTH and mix. 5. Incubate at room temperature for 30 minutes with mixing. 6. Magnetically separate VERAPREP Concentrate PTH using a Dexter LifeSep® 50SX for 15 minutes. 7. Decant and discard 40 mL of PBS. 8. Add 4.0 mL of PBS wash buffer and mix. 9. Magnetically separate VERAPREP Concentrate PTH in 4 mL PBS wash buffer using a Dexter LifeSep® 50SX for 10 minutes. 10. Decant and discard 4 mL of PBS. 11. Add 1.0 mL of PBS wash buffer and mix. 12. Transfer 1 mL of VERAPREP Concentrate PTH to a 1.75 mL conical bottom snap cap vial. 13. Magnetically separate VERAPREP Concentrate PTH in 1 mL PBS wash buffer using a Dexter LifeSep® 1.5S for 10 minutes. 14. Aspirate and discard 1 mL of PBS. 15. Add 1 mL of VERAPREP Cleave and mix. 16. Magnetically separate VERAPREP Concentrate PTH in 1 mL VERAPREP Cleave using Dexter LifeSep® 1.5S for 10 minutes. 17. 1 mL of the supernatant (concentrated sample) was aspirated and saved to test the control, baseline, and concentrated samples.

[0155] 0.021 mL of PTH antigen (971 pg / mL, for ELISA calibration) was also diluted to 20.4 pg / mL in 1 mL of VERAPREP Cleave buffer as a control. The baseline sample, concentrated sample, and control were tested in the DRG PTH (Parathyroid) Intact ELISA, and the PTH recovery of the concentrated sample was calculated as [concentrated sample result] / [control result] × 100%. The diluted PTH baseline sample was 13.5 pg / mL due to the matrix effect of VERAPREP Cleave buffer in the ELISA assay. This matrix effect improved the assay signal. Using only 0.80 mg of reagent, VERAPREP Concentrate PTH successfully concentrated the diluted PTH to 42.3 pg / mL (Table 4). There was 109% recovery compared to the control (Table 5).

[0156] [Table 4]

[0157] [Table 5]

[0158] Example 4: Enrichment of low-level biomarkers from urine for subsequent mass spectrometry (LC-MS / MS or MALDI-MS) analysis Below, we describe a mass spectrometry sample pretreatment protocol for enriching low concentration biomarkers, and spiked internal standards (ISTDs), from large volume urine samples using superparamagnetic nanoparticles coated with biomarker-specific capture sites. The exact same protocol can also use different superparamagnetic nanoparticle populations, mixed or pooled, where each population is coated with a different capture site, to multiplex and enrich two or more biomarkers and corresponding spiked ISTDs from the same sample. Enrichment and characterization of two or more biomarkers facilitates the use of algorithms for clinical diagnosis and / or prognosis of diseases that are not possible with characterization of a single biomarker. For example, to diagnose obstructive sleep apnea (OSA) from urine, the VERAPREP Concentrate reagent may be composed of four antibodies to capture and enrich kallikrein-1, uromodulin, urocortin-3, and orosomucoid-1, or seven antibodies to capture and enrich kallikrein-1, uromodulin, urocortin-3, and orsomucoid-1, IL-6, IL-10, and high sensitivity C-reactive protein. 1. Collect urine from the patient (using standard urine collection protocols, including urine cups). 2. Mix the urine sample. 3. Add 40mL of urine to a 50mL Falcon tube. 4. Add deuterated internal standards for biomarkers for enrichment and mix. 5. Add VERAPREP Condition and mix. 6. Add VERAPREP Concentrate and mix. 7. Incubate: VERAPREP Concentrate captures the biomarkers and deuterated internal standards. 8. Magnetically separate VERAPREP Concentrate in 40 mL of urine using a Dexter LifeSep® 50SX. 9. Aspirate and discard the urine. 10. Add 4 mL of PBS wash buffer and mix. 11. Magnetically separate the VERAPREP Concentrate in 4 mL of PBS Wash Buffer using a Dexter LifeSep® 50SX. 12. Aspirate and discard the urine. 13. Repeat step 12 two more times (2x). 14. Add 1 mL of VERAPREP Cleave and mix (mass spectrometry compatible buffer). 15. Magnetically separate VERAPREP Concentrate in 1 mL VERAPREP Cleave using Dexter LifeSep® 1.5S. 16. A 1 mL sample of the supernatant was aspirated and tested by LC-MS. 17. Final biomarker concentrations were determined based on 1) a 40 mL urine sample size, 2) LC-MS quantification of biomarkers, and 3) adjustment of reported biomarker values ​​based on recovery of deuterated internal standards.

[0159] Selective release or cleavage of the captured and concentrated biomarker(s) can be achieved by a change in pH (acidic pH such as elution with glycine pH 2.5 followed by neutralization, or alkaline pH above pH 10.0), the use of cleavable linkers such as disulfide bonds that are cleaved with reducing agents such as TCEP or DTT, or the use of competitive elution such as a molar excess of D-biotin with monomeric avidin to compete for binding sites on concanavalin A or a molar excess of sugars with concanavalin A.

[0160] (abbreviation) ABEI N-(4-aminobutyl)-N-ethylisoluminol ALP alkaline phosphatase BSA Bovine Serum Albumin Fab fragment antibody binding Fc fragment, crystallizable HAAA Human anti-animal antibody HAMA Human Anti-Mouse Antibody HASA human anti-sheep antibody Instructions for use IFU IgG antibodies or immunoglobulins IgM Immunoglobulin M HRP Horseradish Peroxidase LC-MS / MS Liquid chromatography-tandem mass spectrometry LDT Laboratory Developed Tests Mab Monoclonal Antibody MASI Production Assay Specific Interference MFG IVD Manufacturer PMP superparamagnetic particles PBCT Primary Blood Collection Tube RF Rheumatoid factor RLU Relative Light Units or Assay Response Signal RUO Research Use Only SAv Streptavidin STT Secondary Transfer Tube TAT Turnaround Time WF Workflow

[0161] (definition) As used herein, a "sample" or "biological sample" refers to human or animal serum, plasma (i.e., EDTA, lithium heparin, sodium citrate), blood, whole blood, processed blood, urine, saliva, stool (liquid and solid), semen or seminal plasma, amniotic fluid, cerebrospinal fluid, cells, tissues, biopsies, DNA, RNA, or any liquid or dissolved solid, or processed solid material that is tested for diagnosis, prognosis, screening, risk assessment, severity classification, and monitoring, such as therapeutic drug monitoring. In some embodiments, the sample is a large volume sample. In some embodiments, the sample includes multiple samples (e.g., two or more samples from the same or different subjects). In some embodiments, the sample includes a biomarker that is present in a low concentration in the sample.

[0162] In some embodiments, samples are collected in primary blood collection tubes (PBCT), secondary transfer tubes (SST), 24hr urine collectors, vericore tubes, nanotainers, saliva collection tubes, blood spot filters, or any collection tube or device such as for stool and semen, plasma separator tubes (PST) with light green or green tops containing sodium heparin, lithium heparin, or ammonium heparin, light blue top tubes containing sodium citrate (i.e., 3.2% or 3.8%) or citrate salts, theophylline, adenosine, dipyridamole (CTAD), red top tubes for serology or immunohematology to collect serum in glass tubes (no additives) or plastic tubes (with clot activators), red top tubes for chemistry to collect serum in glass tubes (no additives) or plastic tubes (with clot activators), EDTA K2, EDTA Blood is collected into K3, purple lavender top tubes containing liquid EDTA solution (i.e., 8%) or EDTA K2 / gel tubes, pink top tubes for blood bank EDTA, gray top tubes containing potassium oxalate and sodium fluoride, sodium fluoride / EDTA, or sodium fluoride (no anticoagulant, for serum samples), yellow top tubes containing ACD solution A or ACD solution B, royal blue top tubes (serum, no additives or sodium heparin), white top tubes, or any color or type of tube for blood collection with no additives or any additives, or combinations thereof, for any use or type of diagnostic test.

[0163] In some embodiments, the sample is a difficult type of sample, such as urine, 24-hour urine, saliva, and stool, or where the biomarker of interest is diluted or difficult to measure. For example, biological samples can be difficult due to patient populations (e.g., neonatal, pediatric, geriatric, pregnant, tumor, autoimmune disease). For example, some biomarkers are too diluted or at too low concentrations, e.g., in the circulation or urine, to be reliably detected and accurately and precisely measured by current POCT and major laboratory analyzers. In some embodiments, the difficult sample is cerebrospinal fluid (CSF).

[0164] As used herein, a "collection device" can be a primary blood collection tube (PBCT), a 24-hour urine collector, a urine collector, a saliva collection tube, a stool collector, a semen collector, a blood collection bag, or any sample collection tube or device prior to the addition of a sample.

[0165] PCBT and secondary transfer tubes (SST) may be standard commercially available or custom collection tubes (with or without gel separator) from companies such as Becton Dickinson (BD), Greiner, VWR, and Sigma Aldrich; glass tubes, plastic tubes, plasma separation tubes (PST) with pale green or green tops containing sodium heparin, lithium heparin, or ammonium heparin; pale blue top tubes containing sodium citrate (i.e., 3.2% or 3.8%) or citrate salts, theophylline, adenosine, dipyridamole (CTAD); red top tubes for serology or immunohematology to collect serum in glass tubes (without additives) or plastic tubes (with clot activators); red top tubes for chemistry to collect serum in glass tubes (without additives) or plastic tubes (with clot activators); purple lavender top tubes containing EDTA K2, EDTA K3, liquid EDTA solution (i.e., 8%) or EDTA It may be K2 / gel tubes, pink top tubes for blood bank EDTA, grey top tubes with potassium oxalate and sodium fluoride, sodium fluoride / EDTA, or sodium fluoride (no anticoagulant, for serum samples), yellow top tubes with ACD solution A or ACD solution B, royal blue top tubes (serum, no additives or sodium heparin), white top tubes, or any color or type of tube for blood collection with no additives or any additives, or combinations thereof, for any application or type of diagnostic test.

[0166] As used herein, a "storage device" or "transfer device" refers to a device capable of receiving a sample and / or other components received by a collection device. A storage or transfer device may be a plastic or glass tube, vial, bottle, beaker, flask, bag, can, microtiter plate, ELISA plate, 96-well plate, 384-well plate, 1536-well plate, cuvette, reaction module, reservoir, or any container suitable for holding, storing, or processing a liquid sample.

[0167] As used herein, "diagnostic tests" include, but are not limited to, antibody-based diagnostic tests, non-antibody-based diagnostic tests, methods or devices for sample preparation for subsequent analysis by chromatographic, spectrophotometric, and mass spectrometry methods (i.e., HPLC, MS, LCMS, LC-MS / MS), such as immunoextraction (IE) and solid phase extraction (SPE), radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), molecular diagnostics, lateral flow (LF), point of care (PoC), direct to market (DTC), CLIA and CLIA-waived tests and devices, Research Use Only (RUO) tests, In Vitro Diagnostic (IVD) tests, Laboratory Developed Tests (LDTs), companion diagnostics, and any test for diagnosis, prognosis, screening, risk assessment, staging, and monitoring, such as therapeutic drug monitoring. In some embodiments, diagnostic tests include rapid turnaround time diagnostic tests (STATs), outpatient tests, lateral flow tests, point-of-care (PoC) tests, molecular diagnostic tests, HPLC, MS, LCMS, LC-MS / MS, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), chemiluminescent immunoassays (CLIAs), CLIA and CLIA-waived tests, and any diagnostic test for diagnosis, prognosis, screening, risk assessment, severity stratification, treatment monitoring, and therapeutic drug monitoring.

[0168] (Additional Note) (Appendix 1) 1. A method for isolating a biomarker from a biological sample, comprising: a) combining the sample with particles comprising capture sites to provide a mixture; and b) mixing the mixture to provide a particulate complex with the biomarker; Including, thereby isolating a biomarker from the biological sample; method.

[0169] (Appendix 2) The method of claim 1, further comprising subjecting the particle complex to a diagnostic test.

[0170] (Appendix 3) 1. A method for removing interferents from a biological sample, comprising: a) combining said sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide particle complexes with the interfering substances; and c) removing or completely removing said particle complexes to provide a depleted solution; Including, thereby reducing or decreasing the amount (e.g., mass, molar, concentration) of said interfering substances; method.

[0171] (Appendix 4) The method of claim 3, further comprising subjecting the depleted solution to characterization (e.g., a diagnostic test).

[0172] (Appendix 5) The method of claim 1 or 3, wherein the particles are provided as a lyophilizate (e.g., LyoSphere™ (BIOLYOPH LLC)).

[0173] (Appendix 6) 1. A method for improving accuracy of a diagnostic test, comprising: a) combining a biological sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide particle complexes with the interferents; c) providing a solution in which the particle complexes have been removed or completely removed and depleted; and d) subjecting said depleted solution to a diagnostic test; Including, Thereby improving the accuracy of diagnostic tests, method.

[0174] (Appendix 7) 7. The method of any one of claims 1 to 6, wherein at least 1%, 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 99% of the interfering substances are removed compared to a biological sample not subjected to the method.

[0175] (Appendix 8) 8. The method of any one of claims 1 to 7, wherein a sufficient amount of the interfering substances is removed to provide less than 100 ppm of the interfering substances in the biological sample.

[0176] (Appendix 9) 9. The method of any one of claims 1-8, wherein a sufficient amount of the interfering substance is removed to provide less than a detectable amount of the interfering substance in the biological sample.

[0177] (Appendix 10) 7. The method according to any one of appendix 1 to 6, wherein the capture moiety is a human anti-animal antibody (eg, mouse IgG, sheep IgG, goat IgG, rabbit IgG, bovine IgG, porcine IgG, horse IgG).

[0178] (Appendix 11) The method according to any one of appendix 1 to 6, wherein the capture site is a heterophilic antibody (e.g., FR (Fc-specific), Fab, F(ab)'2, polymerized IgG (type 1, 2a, 2b IgG and IgG fragments), serum components).

[0179] (Appendix 12) 7. The method of any one of claims 1 to 6, wherein the capture moiety is an assay-specific binding agent (e.g., biotin, fluorescein, anti-fluorescein poly / Mab, anti-biotin poly / Mab, streptavidin, neutravidin).

[0180] (Appendix 13) 7. The method of any one of claims 1 to 6, wherein the capture moiety is an assay-specific signal molecule (e.g., HRP, ALP, acridinium ester, isoluminol / luminol, ruthenium, ABEI / cyclic ABEI).

[0181] (Appendix 14) 7. The method of any one of claims 1 to 6, wherein the capture moiety is an assay-specific blocking agent (e.g., BSA, fish skin gelatin, casein, egg albumin, PVP, PVA).

[0182] (Appendix 15) 7. The method of any one of claims 1 to 6, wherein the capture moiety is an assay-specific binding linker (e.g., LC, LC-LC, PEO4, PEO16).

[0183] (Appendix 16) 7. The method of any one of claims 1 to 6, wherein the capture site is an antigen-autoantibody (e.g., free T3, free T4).

[0184] (Appendix 17) 7. The method of any one of claims 1 to 6, wherein the capture site is a protein autoantibody (e.g., MTSH, TnI, TnT, non-cardiac TnT (skeletal muscle disease)).

[0185] (Appendix 18) The method of any one of claims 1 to 6, wherein the capture moiety is a chemiluminescent substrate (e.g., luminol, isoluminol, isoluminol derivatives, ABEI, ABEI derivatives, ruthenium, acridinium esters) or a fluorescent label (e.g., fluorescein or other fluorescent dye molecules, and stains).

[0186] (Appendix 19) The method according to any one of appendix 1 to 6, wherein the capture site is a capture site (e.g., streptavidin, neutravidin, avidin, captavidin, polyA, polyDT, aptamer, antibody, Fab, F(ab')2, antibody fragment, recombinant protein, enzyme, protein, biomolecule, polymer).

[0187] (Appendix 20) 7. The method of any one of claims 1 to 6, wherein the capture moiety is biotin, fluorescein, polyDT, polyA, or an antigen.

[0188] (Appendix 21) 10. The method of any one of claims 1 to 9, wherein the removal, or the complete removal, is separation.

[0189] (Appendix 22) 22. The method of claim 21, wherein the separation comprises physical separation.

[0190] (Appendix 23) 22. The method of claim 21, wherein the separation comprises magnetic separation.

[0191] (Appendix 24) 22. The method of claim 21, wherein the separation comprises chemical separation.

[0192] (Appendix 25) 22. The method of claim 21, wherein the removing, or complete removing, comprises centrifuging at 1000×g or more for at least 1 minute, 2 minutes, 3 minutes, 4 minutes, or 5 minutes to provide a pellet and a supernatant, and removing the supernatant.

[0193] (Appendix 26) 22. The method of claim 21, wherein the removing or complete removing comprises filtration (e.g., passing through a filter).

[0194] (Appendix 27) 27. The method of claim 26, wherein the filter is porous or has a molecular weight cut-off (MWCO) sufficiently smaller than the diameter of the particles (e.g., nanoparticles, microparticles).

[0195] (Appendix 28) 27. The method of claim 26, wherein the filtration is by gravity, vacuum, or centrifugation.

[0196] (Appendix 29) 10. The method of any one of claims 1 to 9, wherein the removing, or the complete removing, comprises magnetizing.

[0197] (Appendix 30) 30. The method of claim 29, wherein the magnetization is performed using a strong magnet (e.g., a neodymium magnet) to provide a pellet and a supernatant.

[0198] (Appendix 31) 31. The method of claim 30, wherein the magnet is in a centrifuge rotor.

[0199] (Appendix 32) 31. The method of claim 30, wherein the magnet is a magnet in a disposable pipette tip, cover, or sheath.

[0200] (Appendix 33) 1. A method for isolating a biomarker from a biological sample, comprising: a) combining said sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide a particle complex comprising the biomarker; c) removing the particle complexes from the mixture; and d) adding a cleavage or release agent to said mixture to provide an isolate comprising the biomarker; Including, thereby isolating biomarkers from the biological sample; method.

[0201] (Appendix 34) 1. A method for determining whether a biomarker is present in a biological sample, comprising: a) combining the sample with capture sites to provide a mixture; b) combining said mixture with particles comprising said capture sites to provide a tertiary complex; c) removing said tertiary complex from said mixture to provide an isolate; and d) determining whether an indication of said tertiary complex is present in said isolate; Including, thereby determining whether the biomarker is present in the biological sample; method.

[0202] (Appendix 35) 1. A method for determining whether a biomarker is present in a biological sample, comprising: a) combining said sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide particle complexes with the interferents; c) removing or completely removing said particle complexes to provide a depleted solution; d) combining the depleted solution with second particles comprising second capture sites to provide a second mixture; e) mixing the second mixture to provide a second particle complex comprising the biomarker; f) removing the second particle complex from the second mixture; and g) adding a cleavage or release agent to said second mixture to provide an isolate comprising said biomarker; Including, thereby isolating biomarkers from the biological sample; method.

[0203] (Appendix 36) 36. The method of any one of claims 33 to 35, further comprising washing the particle complex with a diluent.

[0204] (Appendix 37) 36. The method of claim 33 or 35, wherein the cleavage reagent is a disulfide bond reducing agent.

[0205] (Appendix 38) 36. The method of any one of claims 33-35, further comprising performing a diagnostic test for said biomarker.

[0206] (Appendix 39) 1. A method for enriching the amount of a biomarker in a sample, comprising: a) adding particles comprising capture sites to said sample to provide a mixture; b) mixing the mixture to provide a particle complex; c) separating the particle complexes to provide a pellet and a supernatant; e) removing the supernatant from the pellet; f) washing the pellet with a diluent; and g) eluting the biomarkers from the pellet to provide an enriched sample; Including, thereby concentrating the amount of biomarker in the sample, method.

[0207] (Appendix 40) 40. The method of claim 39, wherein the biomarker is an indicator of traumatic brain injury (TBI).

[0208] (Appendix 41) 40. The method of claim 39, wherein the biomarkers are s-100β, glial fibrillary acidic protein (GFAP), neuronal specific enolase (NSE), neurofilament light chain (NFL), truncated tau protein (C-tau), and ubiquitin C-terminal hydrolase L1 (UCH-L1).

[0209] (Appendix 42) 40. The method of claim 39, wherein the biomarker is an indicator of Alzheimer's disease (AD).

[0210] (Appendix 43) The method of claim 39, wherein the biomarker is amyloid beta, BACE1, or soluble Aβ precursor protein (sAPP).

[0211] (Appendix 44) 40. The method of claim 39, wherein the biomarker is an indicator of a sexually transmitted disease (STD).

[0212] (Appendix 45) 45. The method of claim 44, wherein the STD is chlamydia, gonorrhea, syphilis, trichomoniasis, HPV, herpes, hepatitis B, hepatitis C, or HIV.

[0213] (Appendix 46) 40. The method of claim 39, wherein the biomarker is an indicator of a bacterial infection.

[0214] (Appendix 47) 40. The method of claim 39, wherein the biomarker is a capture site for bacteria.

[0215] (Appendix 48) 40. The method of claim 39, wherein the biomarker is cleaved from the complex by a cleavage reagent.

[0216] (Appendix 49) 40. The method of claim 39, wherein the presence of the biomarker is determined by MALDI-MS.

[0217] (Appendix 50) 4. The method of claim 3, wherein the interfering substance is fibrinogen, and the removal, or complete removal, is a separation, such as a physical separation by centrifugation, and the particle complex is trapped in a thrombus.

Claims

1. 1. A method for isolating a biomarker from a biological sample, comprising: a) combining the sample with particles comprising capture sites to provide a mixture; and b) mixing the mixture to provide particle complexes with the biomarkers; Including, thereby isolating a biomarker from the biological sample; method.

2. The method of claim 1 , further comprising subjecting the particle complex to a diagnostic test.

3. 1. A method for removing interferents from a biological sample, comprising: a) combining said sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide particle complexes with the interfering substances; and c) removing or completely removing said particle complexes to provide a depleted solution; Including, thereby reducing or decreasing the amount (e.g., mass, molar, concentration) of said interfering substances; method.

4. The method of claim 3 , further comprising subjecting the depleted solution to characterization (e.g., a diagnostic test).

5. The method of claim 1 or 3, wherein the particles are provided as a lyophilizate (e.g., LyoSphere™ (BIOLYOPH LLC)).

6. 1. A method for improving accuracy of a diagnostic test, comprising: a) combining a biological sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide particle complexes with the interferents; c) providing a solution from which said particle complexes have been removed or completely removed and depleted; and d) subjecting said depleted solution to a diagnostic test; Including, Thereby improving the accuracy of diagnostic tests, method.

7. 7. The method of any one of claims 1 to 6, wherein at least 1%, 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99% of the interfering substances are removed compared to a biological sample not subjected to the method.

8. 8. The method of any one of claims 1 to 7, wherein a sufficient amount of the interfering substances is removed to provide less than 100 ppm of the interfering substances in the biological sample.

9. 9. The method of any one of claims 1 to 8, wherein a sufficient amount of the interfering substances is removed to provide less than detectable amounts of the interfering substances in the biological sample.

10. The method according to any one of claims 1 to 6, wherein the capture moiety is a human anti-animal antibody (eg mouse IgG, sheep IgG, goat IgG, rabbit IgG, bovine IgG, porcine IgG, equine IgG).

11. The method of any one of claims 1 to 6, wherein the capture moiety is a heterophilic antibody (e.g., FR (Fc-specific), Fab, F(ab)'2, polymerized IgG (type 1, 2a, 2b IgG and IgG fragments), serum component).

12. The method of any one of claims 1 to 6, wherein the capture moiety is an assay-specific binding agent (eg, biotin, fluorescein, anti-fluorescein poly / Mab, anti-biotin poly / Mab, streptavidin, neutravidin).

13. The method of any one of claims 1 to 6, wherein the capture moiety is an assay-specific signal molecule (eg, HRP, ALP, acridinium ester, isoluminol / luminol, ruthenium, ABEI / cyclic ABEI).

14. The method of any one of claims 1 to 6, wherein the capture site is an assay-specific blocking agent (eg, BSA, fish skin gelatin, casein, egg albumin, PVP, PVA).

15. The method of any one of claims 1 to 6, wherein the capture moiety is an assay-specific binding linker (eg LC, LC-LC, PEO4, PEO16).

16. The method of any one of claims 1 to 6, wherein the capture site is an antigen-autoantibody (eg, free T3, free T4).

17. The method of any one of claims 1 to 6, wherein the capture moiety is a protein autoantibody (eg MTSH, TnI, TnT, non-cardiac TnT (skeletal muscle disease)).

18. 7. The method of any one of claims 1 to 6, wherein the capture moiety is a chemiluminescent substrate (e.g., luminol, isoluminol, isoluminol derivatives, ABEI, ABEI derivatives, ruthenium, acridinium esters) or a fluorescent label (e.g., fluorescein or other fluorophores, and stains).

19. The method of any one of claims 1 to 6, wherein the capture moiety is a capture moiety (e.g., streptavidin, neutravidin, avidin, captavidin, polyA, polyDT, aptamer, antibody, Fab, F(ab')2, antibody fragment, recombinant protein, enzyme, protein, biomolecule, polymer).

20. The method of any one of claims 1 to 6, wherein the capture moiety is biotin, fluorescein, polyDT, polyA, or an antigen.

21. The method according to any one of claims 1 to 9, wherein said removal, or said complete removal, is a separation.

22. 22. The method of claim 21, wherein the separation comprises physical separation.

23. The method of claim 21 , wherein the separation comprises magnetic separation.

24. The method of claim 21 , wherein the separation comprises a chemical separation.

25. 22. The method of claim 21, wherein the removing, or the complete removing, comprises centrifugation at 1000×g or more for at least 1 minute, 2 minutes, 3 minutes, 4 minutes or 5 minutes to provide a pellet and a supernatant, and removing the supernatant.

26. 22. The method of claim 21, wherein the removing, or the complete removing, comprises filtration (e.g., passing through a filter).

27. 27. The method of claim 26, wherein the filter is porous or has a molecular weight cut-off (MWCO) that is sufficiently smaller than the diameter of the particles (e.g., nanoparticles, microparticles).

28. 27. The method of claim 26, wherein the filtration is by gravity, vacuum, or centrifugation.

29. The method of any one of claims 1 to 9, wherein the removal, or the complete removal, comprises magnetization.

30. 30. The method of claim 29, wherein the magnetization is performed using a strong magnet (e.g., a neodymium magnet) to provide a pellet and a supernatant.

31. 31. The method of claim 30, wherein the magnet is in a centrifuge rotor.

32. 31. The method of claim 30, wherein the magnet is a magnet in a disposable pipette tip, cover, or sheath.

33. 1. A method for isolating a biomarker from a biological sample, comprising: a) combining said sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide a particle complex comprising the biomarker; c) removing the particle complexes from the mixture; and d) adding a cleavage reagent, or a release agent, to said mixture to provide an isolate comprising the biomarker; Including, thereby isolating biomarkers from the biological sample; method.

34. 1. A method for determining whether a biomarker is present in a biological sample, comprising: a) combining the sample with capture sites to provide a mixture; b) combining said mixture with particles comprising said capture sites to provide a tertiary complex; c) removing said tertiary complex from said mixture to provide an isolate; and d) determining whether an indication of said tertiary complex is present in said isolate; Including, thereby determining whether the biomarker is present in the biological sample; method.

35. 1. A method for determining whether a biomarker is present in a biological sample, comprising: a) combining said sample with particles comprising capture sites to provide a mixture; b) mixing the mixture to provide particle complexes with the interferents; c) removing or completely removing said particle complexes to provide a depleted solution; d) combining the depleted solution with second particles comprising second capture sites to provide a second mixture; e) mixing the second mixture to provide a second particle complex comprising the biomarker; f) removing the second particle complex from the second mixture; and g) adding a cleavage or release agent to said second mixture to provide an isolate comprising said biomarker; Including, thereby isolating biomarkers from the biological sample; method.

36. The method of any one of claims 33 to 35, further comprising washing the particle complexes with a diluent.

37. 36. The method of claim 33 or 35, wherein the cleavage reagent is a disulfide bond reducing agent.

38. The method of any one of claims 33 to 35, further comprising performing a diagnostic test for said biomarker.

39. 1. A method for enriching the amount of a biomarker in a sample, comprising: a) adding particles comprising capture sites to said sample to provide a mixture; b) mixing the mixture to provide a particle complex; c) separating the particle complexes to provide a pellet and a supernatant; e) removing the supernatant from the pellet; f) washing the pellet with a diluent; and g) eluting the biomarkers from the pellet to provide an enriched sample; Including, thereby concentrating the amount of biomarker in the sample, method.

40. 40. The method of claim 39, wherein the biomarker is an indicator of traumatic brain injury (TBI).

41. 40. The method of claim 39, wherein the biomarkers are s-100β, glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), neurofilament light chain (NFL), truncated tau protein (C-tau), and ubiquitin C-terminal hydrolase L1 (UCH-L1).

42. 40. The method of claim 39, wherein the biomarker is indicative of Alzheimer's disease (AD).

43. 40. The method of claim 39, wherein the biomarker is amyloid beta, BACE1, soluble Aβ precursor protein (sAPP).

44. 40. The method of claim 39, wherein the biomarker is indicative of a sexually transmitted disease (STD).

45. 45. The method of claim 44, wherein the STD is chlamydia, gonorrhea, syphilis, trichomoniasis, HPV, herpes, hepatitis B, hepatitis C, or HIV.

46. 40. The method of claim 39, wherein the biomarker is an indicator of a bacterial infection.

47. 40. The method of claim 39, wherein the biomarker is a capture site for bacteria.

48. 40. The method of claim 39, wherein the biomarker is cleaved from the complex by a cleavage reagent.

49. 40. The method of claim 39, wherein the presence of the biomarker is determined by MALDI-MS.

50. 4. The method of claim 3, wherein the interfering substance is fibrinogen, and the removal, or complete removal, is a separation, such as a physical separation by centrifugation, and the particle complex is trapped in a thrombus.

Citation Information

Patent Citations

  • Detection of substance bondable specifically in body liquor and reagent receptor

    JP1990309254A

  • Magnetic particles for specific capturing and its manufacturing method

    JP2007085929A

  • Anti-HIV (human immunodeficiency virus) antibody detection reagent, reagent kit, manufacturing method of reagent, and detecting method of Anti-HIV antibody

    JP2008051780A

  • Lateral flow assays and devices using magnetic particles

    JP2009503451A

  • Stable dispersion of nanomagnetic particles

    JP2018514794A